EP4359528A1 - Combinaisons d'arnsi ciblant les transcrits du sras-cov-2 et/ou du facteur hôte - Google Patents

Combinaisons d'arnsi ciblant les transcrits du sras-cov-2 et/ou du facteur hôte

Info

Publication number
EP4359528A1
EP4359528A1 EP22738426.0A EP22738426A EP4359528A1 EP 4359528 A1 EP4359528 A1 EP 4359528A1 EP 22738426 A EP22738426 A EP 22738426A EP 4359528 A1 EP4359528 A1 EP 4359528A1
Authority
EP
European Patent Office
Prior art keywords
sequence
sirnas
nos
seq
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22738426.0A
Other languages
German (de)
English (en)
Inventor
Michael Hannus
Stefan Finke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpine Antiviral GmbH
Original Assignee
Alpine Antiviral GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpine Antiviral GmbH filed Critical Alpine Antiviral GmbH
Publication of EP4359528A1 publication Critical patent/EP4359528A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Definitions

  • This invention relates to the field of siRNA combinations targeting coronavirus (SARS-CoV-2) transcripts and/or host factor transcripts.
  • the invention further relates to siRNA combinations and pharmaceutical compositions comprising said siRNA combinations for use in the treatment and prophylaxis of coronavirus infections, particularly coronavirus disease 2019.
  • the SARS-CoV-2 a newly identified b-coronavirus, (Order: Nidovirales, Family: Coronaviridae, Genus: Betacoronavirus) is the causative agent of the third large-scale pandemic in the last two decades. Coronaviruses are widely known virulent pathogens and six globally distributed species of the virus have been identified to cause illness in humans:
  • SARS-CoV Severe acute respiratory syndrome coronavirus
  • MERS-CoV Middle East respiratory syndrome coronavirus
  • SARS CoV-2 forms spherical enveloped particles of lOOnm in diameter which contain a single (+) stranded RNA genome of 30kb.
  • the genome encodes 16 non- structural proteins (Nspl - Nspl6) and the structural proteins M, S, N and E.
  • ACE-2 angiotensin converting enzyme 2
  • TMPRSS2 angiotensin converting enzyme 2
  • Viral entry is mediated by endocytosis and release into the cytoplasm by membrane fusion.
  • the released RNA genome is translated by the host cell thereby generating a viral encoded RNA dependent RNA polymerase, which then transcribes multiple copies of viral genomes and subgenomic RNAs.
  • RNA genomes After expression of structural proteins, the newly formed single stranded RNA genomes are assembled into new viral particles, enveloped in cellular lipids in ER derived compartments and secreted from the host cell.
  • a single infected host cell can release around 1000 viruses within 1 day.
  • the invention is based on the finding that a combination of siRNAs exhibits an antiviral effect against SARS-CoV-2.
  • the inventors could show that the siRNA combinations of the invention reduce or eliminate SARS-CoV-2 infection.
  • host factor targets were found which reduce or eliminate SARS-CoV-2 infection.
  • coronavirus disease preferably coronavirus 2019 disease, can be treated with the siRNA combinations of the invention.
  • the present invention relates to a combination of siRNAs that is targeted to one or more SARS-CoV-2 transcripts and/or host factor transcripts. It is understood, that siRNAs targeting viral transcripts also target the corresponding sequence in the viral genome, being a single (+) stranded RNA genome.
  • the present invention relates to a combination of siRNAs which inhibits the expression of one or more SARS-CoV-2 genes and/or host factor genes in vitro , such as e.g., in a cell, or ex vivo in a cell in culture, or in vivo in a cell within a subject.
  • the subject may be a mammal, such as, e.g., a rat, mouse, or human. In some embodiments, the subject may be a human.
  • the invention provides a combination of siRNAs targeted to one or more SARS-CoV-2 transcripts.
  • the invention provides a combination of siRNAs targeted to one or more host factor transcripts.
  • the combination comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 siRNAs of different sequences. Using multiple siRNAs in one siRNA combination has the advantage of reducing the danger of off-target effects and/or increasing gene silencing efficiency.
  • the combination comprises at least 8 siRNAs of different sequences.
  • the combination comprises at least 10 siRNAs of different sequences.
  • the combination comprises at least 9 siRNAs of different sequences.
  • the combination comprises at least 12 siRNAs of different sequences.
  • the combination comprises at least 13 siRNAs of different sequences.
  • the combination comprises at least 14 siRNAs of different sequences. In one embodiment, the combination comprises at least 15 siRNAs of different sequences. In one embodiment, the combination comprises at least 17 siRNAs of different sequences. In one embodiment, the combination comprises at least 18 siRNAs of different sequences. In one embodiment, the combination comprises at least 19 siRNAs of different sequences. In one embodiment, the combination comprises at least 20 siRNAs of different sequences.
  • the combination comprises from 10 to 60 siRNAs of different sequences. In one embodiment, the combination comprises from 10 to 40 siRNAs of different sequences. In one embodiment, the combination comprises from 12 to 30 siRNAs of different sequences. In one embodiment, the combination comprises from 8 to 22 siRNAs of different sequences. In one embodiment, the combination comprises from 10 to 20 siRNAs of different sequences. In one embodiment, the combination comprises from 10 to 15 siRNAs of different sequences. In one embodiment, the combination comprises from 12 to 15 siRNAs of different sequences. In one embodiment, the combination comprises from 18 to 22 siRNAs of different sequences.
  • the above combinations comprising different sequences can be directed against one target transcript or more than one target transcript.
  • the above combinations comprising different sequences can also be combined (multiple combinations of siRNAs each comprising different siRNAs of different sequences) and directed against one target transcript or more than one target transcript.
  • a combination comprising 12 to 15 siRNAs of different sequences can be directed against one target transcript.
  • a combination comprising 12 to 15 siRNAs of different sequences can be directed against more than one target transcript.
  • Multiple combinations of siRNAs each comprising 12 to 15 siRNAs of different sequences can be directed against one target transcript or more than one target transcript.
  • each siRNA is a double- stranded siRNA comprising a sense strand and an antisense strand.
  • the sense strand and antisense strand of the siRNA form a duplex structure.
  • the duplex region of the siRNA may have at least 11 base pairs, such as, e.g., at least 15 base pairs, at least 17 base pairs, or at least 19 base pairs.
  • the duplex region of the siRNA may have 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 or 27 base pairs.
  • the duplex region of the siRNA may have 16 base pairs.
  • the duplex region of the siRNA may have 17 base pairs.
  • the duplex region of the siRNA may have 19 base pairs.
  • the duplex region of the siRNA may have 21 base pairs.
  • the length of the duplex region of the siRNAs in the combination according to the invention is independent of each other.
  • each siRNA is independently between about 10 and about 60 nucleotides in length. In one embodiment, each siRNA is independently between 10 to 30 base pairs in length. In one embodiment, each siRNA is independently between 10 to 27 base pairs in length. In one embodiment, each siRNA is independently between 15 to 27 base pairs in length. In one embodiment, each siRNA is independently between 15 to 25 base pairs in length. In one embodiment, each siRNA is independently between 17 to 23 base pairs in length. In one embodiment, each siRNA is independently between 18 to 20 base pairs in length. In one embodiment, each siRNA is 19 base pairs in length.
  • each strand of the siRNA may have the same length or different lengths.
  • each strand of the siRNA may be 10-29 nucleotides in length.
  • each strand may be 13-29 nucleotides in length, 16-28 nucleotides in length, 16-27 nucleotides in length, 16-25 nucleotides in length, 16-27 nucleotides in length, or 16-23 nucleotides in length, including all integers in between these ranges.
  • each strand may be 19-21 nucleotides in length, including 20 nucleotides.
  • each strand may be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 or 27 nucleotides in length.
  • each strand may be 16 nucleotides in length. In some embodiments, each strand may be 19 nucleotides in length. In some embodiments, each strand may be 21 nucleotides in length. In a preferred embodiment, each strand may be 19 nucleotides in length.
  • the lengths of each strand of each siRNA can be identical or can be different. For the purpose of this disclosure, length calculation of any double-stranded siRNA strands shall exclude any nucleotide overhangs that may be present.
  • the combination of siRNAs is targeted to one or more SARS- CoV-2 transcripts and/or host factor transcripts, and comprises at least two siRNAs of different sequences, wherein each siRNA comprises an antisense strand and a complementary sense strand.
  • Each siRNA of the combination according to the invention may comprise nucleotide insertions, substitutions, deletions, or mismatches.
  • sense and antisense strands of siRNAs which may each comprise a nucleotide sequence having at least 75%, such as, e.g., at least at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or higher identity to any one of the disclosed sequences.
  • a siRNA strand i.e. a sense or antisense strand of 19 nucleotides with 75% identity to a disclosed sequence has 4 inserted, substituted, deleted or mismatched nucleotides.
  • a siRNA strand of 19 nucleotides with 80% identity to a disclosed sequence has 3 inserted, substituted, deleted or mismatched nucleotides.
  • a siRNA strand of 19 nucleotides with 85% identity to a disclosed sequence has 2 inserted, substituted, deleted or mismatched nucleotides.
  • a siRNA strand of 19 nucleotides with 90% identity to a disclosed sequence has 1 inserted, substituted, deleted or mismatched nucleotide.
  • a siRNA strand i.e. a sense or antisense strand of 21 nucleotides with 75% identity to a disclosed sequence has 5 inserted, substituted, deleted or mismatched nucleotides.
  • a siRNA strand of 21 nucleotides with 80% identity to a disclosed sequence has 4 inserted, substituted, deleted or mismatched nucleotides.
  • a siRNA strand of 21 nucleotides with 85% identity to a disclosed sequence has 3 inserted, substituted, deleted or mismatched nucleotides.
  • a siRNA strand of 21 nucleotides with 90% identity to a disclosed sequence has 2 inserted, substituted, deleted or mismatched nucleotides.
  • a siRNA strand of 21 nucleotides with 95% identity to a disclosed sequence has 1 inserted, substituted, deleted or mismatched nucleotide.
  • insertions, substitutions, deletions or mismatches may be independently present in the sense and/or antisense strand.
  • the double-stranded siRNA described herein may comprise one or more single-stranded nucleotide overhangs of one or more nucleotides at the 5’-end, 3’-end, or both ends of one or both strands.
  • the nucleotide overhangs on each strand may be the same or different in terms of number, length, sequence, and location.
  • the nucleotide overhang may be located at the 3’ -end of the sense strand, the antisense strand, or both strands.
  • the siRNA may also have a blunt end, located at the 5’-end of the antisense strand (or the 3’-end of the sense strand) or vice versa.
  • the antisense strand of the siRNA may have a nucleotide overhang at the 3’ -end and a blunt 5’ -end.
  • the overhang may form a mismatch with the target sequence or it may be complementary to the target sequence or may be another sequence.
  • at least one end of either strand of the siRNA may comprise a nucleotide overhang of 1-5 nucleotides in length, such as, e.g., 1-5, 2-5, 1-4, 2-4, 1-3, 2-3 or 1-2 nucleotides, including all integers in between these ranges.
  • the nucleotide overhang may have 1 or 2 nucleotides in length.
  • the nucleotides in the overhang may each independently be an unmodified nucleotide or a modified nucleotide as disclosed herein or known in the art.
  • the nucleotide overhang may be 2 nucleotides.
  • the antisense strand of the siRNA may have 2 nucleotides at the 3’- end.
  • the sense strand of the siRNA may have 2 nucleotides at the 3’-end.
  • both strands of the siRNA may have 2 nucleotides at the 3’-end.
  • the nucleotide overhang may be AG.
  • the antisense strand of the siRNA may have AG at the 3’- end. In some embodiments, the sense strand of the siRNA may have AG at the 3’-end. In some embodiments, both strands of the siRNA may have AG at the 3’ -end. In one embodiment, both strands of each siRNA of the siRNA combination, wherein the strands of the single siRNAs are disclosed in Table 1 or Table 2, have an AG overhang at the 3’ -end. When two or more different siRNA molecules are used in combination, each siRNA may have the same or different overhang architectures. For example, the number, length, sequence, and location of the nucleotide overhang on each strand may be independently selected.
  • siRNAs of the present invention can be chemically synthesized, expressed from a vector or enzymatically synthesized.
  • An exemplary enzymatic synthesis is described in WO 2013/160393 using RNase Tl.
  • each siRNA is a double- stranded siRNA comprising a sense strand and an antisense strand.
  • the siRNAs are either defined based on the antisense or sense sequences. If the siRNAs of the invention are defined based on antisense sequences, it is to be understood, that each siRNA will contain the respective antisense sequence and a complementary sense sequence. Vice versa, if the siRNAs of the invention are defined based on sense sequences, it is to be understood, that each siRNA will contain the respective sense sequence and a complementary antisense sequence.
  • Sense and antisense sequences can be fully complementary or substantially complementary meaning that the siRNAs may contain a certain number of inserted, substituted, deleted and/or mismatched nucleotides, e.g. 1, 2, 3 or 4 inserted, substituted, deleted and/or mismatched nucleotides. Insertions, substitutions, deletions and/or mismatches are independently chosen and can be combined differently for each sequence.
  • siRNA sequences targeted to SARS-CoV-2 and/or host factor transcripts siRNA sequences targeted to viral transcripts are summarized in Table 1.
  • siRNA sequences targeted to host factor transcripts are summarized in Table 2. If it is referred to a certain SEQ ID No. in the following, the corresponding sequence is listed in Table 1 or 2.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 1094, wherein each sequence is independently at least about 75% identical to a sequence of SEQ ID NOs: 548 to 1094. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 1094, wherein each sequence is independently at least about 80% identical to a sequence of SEQ ID NOs: 548 to 1094. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 1094, wherein each sequence is independently at least about 85% identical to a sequence of SEQ ID NOs: 548 to 1094.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 1094, wherein each sequence is independently at least about 90% identical to a sequence of SEQ ID NOs: 548 to 1094. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 1094, wherein each sequence is independently at least about 95% identical to a sequence of SEQ ID NOs: 548 to 1094. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 1094, wherein each sequence is independently at least about 98% identical to a sequence of SEQ ID NOs: 548 to 1094.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 1094. In one embodiment, the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 548 to 950 and 975 to 1094, wherein each sequence is independently at least about 75% identical to a sequence of SEQ ID NOs: 548 to 950 and 975 to 1094. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950 and 975 to 1094, wherein each sequence is independently at least about 80% identical to a sequence of SEQ ID NOs: 548 to 950 and 975 to 1094.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950 and 975 to 1094, wherein each sequence is independently at least about 85% identical to a sequence of SEQ ID NOs: 548 to 950 and 975 to 1094. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950 and 975 to 1094, wherein each sequence is independently at least about 90% identical to a sequence of SEQ ID NOs: 548 to 950 and 975 to 1094.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950 and 975 to 1094, wherein each sequence is independently at least about 95% identical to a sequence of SEQ ID NOs: 548 to 950 and 975 to 1094. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950 and 975 to 1094, wherein each sequence is independently at least about 98% identical to a sequence of SEQ ID NOs: 548 to 950 and 975 to 1094. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950 and 975 to 1094.
  • siRNA sequences targeted to SARS-CoV-2 transcripts are directed to one or more SARS-CoV-2 transcripts.
  • the SARS- CoV-2 transcripts are selected from the group comprising the spike protein transcript, envelope protein transcript, nucleocapsid protein transcript, membrane protein transcript and/or Orflab polyprotein transcript.
  • the SARS-CoV-2 transcripts are selected from the group comprising the spike protein transcript, nucleocapsid protein transcript and/or membrane protein transcript.
  • the SARS-CoV-2 transcripts are selected from the group comprising the nucleocapsid protein transcript and membrane protein transcript.
  • the SARS-CoV-2 transcripts are selected from the group comprising the nucleocapsid protein transcript and Orflab polyprotein transcript.
  • the siRNAs are directed to the Orflab polyprotein transcript and/or the nucleocapsid protein transcript.
  • the siRNAs are directed to the Orflab polyprotein transcript and the nucleocapsid protein transcript.
  • the siRNAs are directed to the Orflab polyprotein transcript.
  • the siRNAs are directed to the nucleocapsid protein transcript
  • the siRNAs of the combination according to the invention are directed to one SARS-CoV-2 transcript. In one embodiment, the siRNAs of the combination are directed to the Orflab polyprotein transcript. In one embodiment, the siRNAs of the combination are directed to the nucleocapsid protein transcript. In one embodiment, the siRNAs of the combination are directed to the membrane protein transcript. In one embodiment, the siRNAs of the combination are directed to the spike protein transcript. In one embodiment, the siRNAs of the combination according to the invention are directed to two or more SARS-CoV-2 transcripts. In one embodiment, the siRNAs of the combination are directed to SARS-CoV-2 transcripts comprising the Orflab polyprotein transcript and the nucleocapsid protein transcript.
  • transcripts above refer to the reference genome from NCBI (accession number NC 045512.2).
  • the transcripts mentioned in the above embodiments are transcripts as based on the reference genome from NCBI (accession number NC_045512.2) or a sequence which is 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to it. If it is referred to the membrane protein transcript (M), nucleocapsid protein transcript (N), spike protein transcript (S) or Orfla/b polyprotein transcript (Orfla/b) herein, said transcripts can be based on the sequences SEQ ID No.
  • siRNA sequences targeted to viral transcripts are summarized in Table 1 below. If it is referred to a certain SEQ ID No. in the following, the corresponding sequence is listed in Table 1. siRNAs based on antisense sequences
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is independently at least about 75% identical to a sequence of SEQ ID NOs: 548 to 974. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is independently at least about 80% identical to a sequence of SEQ ID NOs: 548 to 974. In one embodiment, the antisense sequences of the siRNAs are independently selected from 548 to 974, wherein each sequence is independently at least about 85% identical to a sequence of SEQ ID NOs: 548 to 974.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is independently at least about 90% identical to a sequence of SEQ ID NOs: 548 to 974. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is independently at least about 95% identical to a sequence of SEQ ID NOs: 548 to 974. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is independently at least about 98% identical to a sequence of SEQ ID NOs: 548 to 974. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is independently at least about 75% identical to a sequence of SEQ ID NOs: 548 to 950. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is independently at least about 80% identical to a sequence of SEQ ID NOs: 548 to 950. In one embodiment, the antisense sequences of the siRNAs are independently selected from 548 to 950, wherein each sequence is independently at least about 85% identical to a sequence of SEQ ID NOs: 548 to 950.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is independently at least about 90% identical to a sequence of SEQ ID NOs: 548 to 950. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is independently at least about 95% identical to a sequence of SEQ ID NOs: 548 to 950. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is independently at least about 98% identical to a sequence of SEQ ID NOs: 548 to 950. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950.
  • the siRNAs are directed to the Orflab polyprotein transcript.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 720 to 869; wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 720 to 869; wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 720 to 869; wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 720 to 869; wherein each sequence is independently at least about 90% identical to the corresponding sequence. In another preferred embodiment, the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 720 to 869; wherein each sequence is independently at least about 95% identical to the corresponding sequence. In another preferred embodiment, the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 720 to 869; wherein each sequence is independently at least about 98% identical to the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 720 to 869.
  • the siRNAs are directed to the nucleocapsid protein transcript.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 590 to 634, wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 590 to 634, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 590 to 634, wherein each sequence is independently at least about 85% identical to the corresponding sequence. In another preferred embodiment, the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 590 to 634, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In another preferred embodiment, the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 590 to 634, wherein each sequence is independently at least about 95% identical to the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 590 to 634, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In another preferred embodiment, the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 590 to 634.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 620 to 634 (siRNA combination SARS-CoV-2-N-p3 according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 620 to 634, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 620 to 634, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 620 to 634, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 620 to 634, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 620 to 634, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 620 to 634.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 765 to 779 (siRNA combination SARS-CoV-2-orflab-p3 according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 765 to 779, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 765 to 779, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequence SEQ ID Nos: 765 to 779, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequence SEQ ID Nos: 765 to 779, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequence SEQ ID Nos: 765 to 779, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 765 to 779.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 810 to 824 (siRNA combination SARS-CoV-2-orflab-p6 according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 810 to 824, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 810 to 824, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 810 to 824, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 810 to 824, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 810 to 824, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 810 to 824.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 750 to 764 (siRNA combination SARS-CoV-2-orflab-p2 according to Table 1), wherein each siRNA is independently at least about 75% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 750 to 764, wherein each siRNA is independently at least about 80% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 750 to 764, wherein each siRNA is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least SEQ ID Nos: 750 to 764, wherein each siRNA is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 750 to 764, wherein each siRNA is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 750 to 764, wherein each siRNA is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 750 to 764.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 840 to 854 (siRNA combination SARS-CoV-2-orflab-p8 according to Table 1). In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 605 to 619 (siRNA combination SARS-CoV-2-N-p2 according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 605 to 619, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 605 to 619, wherein each sequence is independently at least about 85% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 605 to 619, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 605 to 619, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 605 to 619, wherein each sequence is independently at least about 98% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 605 to 619. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 720 to 734 (siRNA combination SARS-CoV-2-orflab-pl according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 720 to 734, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 720 to 734, wherein each sequence is independently at least about 85% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 720 to 734, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 720 to 734, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 720 to 734, wherein each sequence is independently at least about 98% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 720 to 734. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 825 to 839 (siRNA combination SARS-CoV-2-orflab-p7 according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 825 to 839, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 825 to 839, wherein each sequence is independently at least about 85% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 825 to 839, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 825 to 839, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 825 to 839, wherein each sequence is independently at least about 98% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 825 to 839. In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 855 to 869 (siRNA combination SARS-CoV-2-orflab-p9 according to Table 1).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 710 to 719 (siRNA combination SARS-CoV-2-orflO according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 710 to 719, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 710 to 719, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 710 to 719, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 710 to 719, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 710 to 719, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 710 to 719.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 735 to 749 (siRNA combination SARS-CoV-2-orflab-plO according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 735 to 749, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 735 to 749, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 735 to 749, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 735 to 749, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 735 to 749, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 735 to 749.
  • the combination of siRNAs comprises SEQ ID NOs: 548 to 1094 and 1320 to 1520 (all siRNA combinations targeted to viral transcripts according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1320 to 1331 (siRNA combination SARS-CoV-2-N-rgnl-p2 according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1332 to 1343 (siRNA combination SARS-CoV-2-N-rgn2-pl according to Table 1).
  • the combination of siRNAs comprises at least SEQ ID Nos: 1344 to 1355 (siRNA combination SARS-CoV-2-orflab-rgnl-pl according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1356 to 1367 (siRNA combination SARS-CoV-2-orflab-rgnl-p2 according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1368 to 1379 (siRNA combination SARS-CoV-2-orflab-rgn2-pl according to Table 1).
  • the combination of siRNAs comprises at least SEQ ID Nos: 1380 to 1390 (siRNA combination SARS-CoV-2-orflab-rgn3-pl according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1391 to 1402 (siRNA combination SARS-CoV-2-orflab-rgn4-pl according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1403 to 1413 (siRNA combination SARS-CoV-2-orflab-rgn4-p2 according to Table 1).
  • the combination of siRNAs comprises at least SEQ ID Nos: 1414 to 1424 (siRNA combination SARS-CoV-2-orflab-rgn5-pl according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1425 to 1436 (siRNA combination SARS-CoV-2-orflab-rgn6-pl according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1437 to 1448 (siRNA combination SARS-CoV-2-orflab-rgn6-p2 according to Table 1).
  • the combination of siRNAs comprises at least SEQ ID Nos: 1449 to 1460 (siRNA combination SARS-CoV-2-orflab-rgn6-p3 according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1461 to 1472 (siRNA combination SARS-CoV-2-orflab-rgn7-pl according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1473 to 1484 (siRNA combination SARS-CoV-2-orflab-rgn7-p2 according to Table 1).
  • the combination of siRNAs comprises at least SEQ ID Nos: 1485 to 1496 (siRNA combination SARS-CoV-2-orflab-rgn7-p3 according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1497 to 1508 (siRNA combination SARS-CoV-2-orflab-rgn7-p4 according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1509 to 1520 (siRNA combination SARS-CoV-2-orflab-rgn7-p5 according to Table 1).
  • the combination of siRNAs comprises at least SEQ ID Nos: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847 (siRNA combination Cov-best-pl according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 724, 837, 818, 732, 623, 734, 628, 612, 848, 729 (siRNA combination Cov-best-p2 according to Table 1).
  • the combination of siRNAs comprises at least SEQ ID Nos: 854, 840, 810, 728, 633, 850, 822, 634, 827, 823 (siRNA combination Cov-best-p3 according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729 (siRNA combination Cov-best-pl +Cov-best-p2, also termed Cov-best- pl +p2 according to Table 1).
  • the combination of siRNAs comprises at least SEQ ID Nos: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729, 854, 840, 810, 728, 633, 850, 822, 634, 827, 823 (siRNA combination Cov-best-pl +Cov-best-p2+Cov-best-p3, also termed Cov-best-pl +p2+p3, according to Table 1).
  • each antisense sequence of the above described combinations e.g. SARS-CoV-2-N-rgnl-p2, SARS-CoV-2-N-rgn2-pl, SARS-CoV-2-orflab-rgnl- pl, S ARS-CoV-2-orf 1 ab-rgn 1 -p2, SARS-CoV-2-orflab-rgn2-pl, SARS-CoV-2- orflab-rgn3-pl, SARS-CoV-2-orflab-rgn4-pl, SARS-CoV-2-orflab-rgn4-p2 SARS- CoV-2-orflab-rgn5-pl SARS-CoV-2-orflab-rgn6-pl SARS-CoV-2-orflab-rgn6-p2 SARS-CoV-2-orflab-rgn6-p3, SARS-CoV-2-orflab-rgn7-pl
  • each sequence is independently at least about 80% identical to the corresponding sequence. In one embodiment, each sequence is independently at least about 85% identical to the corresponding sequence. In one embodiment, each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, each sequence is independently at least about 98% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729 (siRNA combination Cov-best-pl+p2 according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729, wherein each sequence is independently at least about 90% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729, wherein each sequence is independently at least about 95% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729, wherein each sequence is independently at least about 98% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID Nos: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729.
  • each of the above described combination of siRNAs may comprise less than the described sequences (i.e. less siRNAs).
  • each of the above described combination of siRNAs comprises at least 5 siRNAs comprising 5 different antisense sequences out of the SEQ ID Nos as mentioned for the respective combination (i.e. at least 5 siRNAs).
  • the combination of siRNAs comprises at least 8 siRNAs comprising at least 8 different antisense sequences of the above SEQ ID Nos (i.e. at least 8 siRNAs). This especially applies to the siRNA combinations comprising 10 antisense sequences, but can also apply to siRNA combinations comprising 12, 15 or 20 antisense sequences.
  • the combination of siRNAs comprises at least 10 siRNAs comprising at least 10 different antisense sequences of the above SEQ ID Nos (i.e. at least 10 siRNAs). This especially applies to the siRNA combinations comprising 12 antisense sequences, but can also apply to siRNA combinations comprising 15 or 20 antisense sequences.
  • the combination of siRNAs comprises at least 13 siRNAs comprising at least 13 different antisense sequences of the above SEQ ID Nos. This especially applies to the siRNA combinations comprising 15 antisense sequences, but can also apply to siRNA combinations comprising 20 antisense sequences.
  • the combination of siRNAs comprises at least 15 siRNAs comprising at least 15 different antisense sequences of the above SEQ ID Nos.
  • the combination of siRNAs comprises at least 17 siRNAs comprising at least 17 different antisense sequences of the above SEQ ID Nos. In one embodiment, the combination of siRNAs comprises at least 18 siRNAs comprising at least 18 different antisense sequences of the above SEQ ID Nos. In one embodiment, the combination of siRNAs comprises at least 19 siRNAs comprising at least 19 different antisense sequences of the above SEQ ID Nos. This applies to the siRNA combinations comprising 20 antisense sequences, such as, e.g. cov-best-pl+p2.
  • the siRNA combination comprises at least 10 or 11 siRNAs of different sequences, wherein the antisense strand of each of the 10 or 11 siRNAs has a sequence selected from the following groups:
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination comprises at least 10, 11, 12, 13, 14 or 15 siRNAs of different sequences, wherein the antisense strand of each of the 10, 11,
  • siRNAs has a sequence selected from the following groups:
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination consists of 10, 11, 12, 13, 14 or 15 siRNAs of different sequences, wherein the antisense strand of each of the 10, 11, 12, 13, 14 or 15 siRNAs has a sequence selected from the following groups: (a) SEQ ID Nos: 590 to 604 (SARS-CoV-2-N-pl); or
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination comprises at least 10 or 11 siRNAs of different sequences, wherein the antisense strand of each of the 10 or 11 siRNAs has a sequence selected from the following groups:
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination consists of 10, 11 or 12 siRNAs of different sequences, wherein the antisense strand of each of the 10, 11 or 12 siRNAs has a sequence selected from the following groups: (a) SEQ ID Nos: 1320 to 1331 (SARS-CoV-2-N-rgnl-p2); or
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination comprises at least 10, 11, 12, 13, 14 or 15 siRNAs of different sequences, wherein the antisense strand of each of the 10, 11,
  • siRNAs has a sequence selected from the following groups:
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination comprises at least 9 or 10 siRNAs of different sequences, wherein the antisense strand of each of the 9 or 10 siRNAs has a sequence selected from the following groups: (a) SEQ ID Nos: 1344 to 1355 (SARS-CoV-2-orflab-rgnl-pl); or (b) SEQ ID Nos: 1356 to 1367 (SARS-CoV-2-orflab-rgnl-p2); or
  • SEQ ID Nos: 1380 to 1390 SARS-CoV-2-orflab-rgn3-pl
  • SEQ ID Nos: 1391 to 1402 SARS-CoV-2-orflab-rgn4-pl
  • SEQ ID Nos: 1403 to 1413 SARS-CoV-2-orflab-rgn4-p2
  • SEQ ID Nos: 1437 to 1448 SARS-CoV-2-orflab-rgn6-p2; or
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination comprises at least 10, 11, 12, 13 or 14 siRNAs of different sequences, wherein the antisense strand of each of the 10, 11, 12, 13 or 14 siRNAs has a sequence selected from the following groups:
  • SEQ ID Nos: 750 to 764 SARS-CoV-2-orflab-p2; or (c) SEQ ID Nos: 765 to 779 (SARS-CoV-2-orflab-p3); or (d) SEQ ID Nos: 780 to 794 (SARS-CoV-2-orflab-p4); or
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination consists of 10, 11, 12, 13, 14 or 15 siRNAs of different sequences, wherein the antisense strand of each of the 10, 11, 12, 13, 14 or 15 siRNAs has a sequence selected from the following groups:
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination comprises at least 9 or 10 siRNAs of different sequences, wherein the antisense strand of each of the 9 or 10 siRNAs has a sequence selected from the following groups:
  • SEQ ID Nos: 1344 to 1355 SARS-CoV-2-orflab-rgnl-pl
  • SEQ ID Nos: 1356 to 1367 SARS-CoV-2-orflab-rgnl-p2
  • SEQ ID Nos: 1380 to 1390 SARS-CoV-2-orflab-rgn3-pl
  • SEQ ID Nos: 1391 to 1402 SARS-CoV-2-orflab-rgn4-pl
  • SEQ ID Nos: 1403 to 1413 SARS-CoV-2-orflab-rgn4-p2; or (g) SEQ ID Nos: 1414 to 1424 (SARS-CoV-2-orflab-rgn5-pl); or (h) SEQ ID Nos: 1425 to 1436 (SARS-CoV-2-orflab-rgn6-pl); or
  • SEQ ID Nos: 1437 to 1448 SARS-CoV-2-orflab-rgn6-p2; or
  • SEQ ID Nos: 1461 to 1472 SARS-CoV-2-orflab-rgn7-pl
  • SEQ ID Nos: 1473 to 1484 SARS-CoV-2-orflab-rgn7-p2
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination consists of 10 or 11 siRNAs of different sequences, wherein the antisense strand of each of the 10 or 11 siRNAs has a sequence selected from the following groups:
  • SEQ ID Nos: 1380 to 1390 SARS-CoV-2-orflab-rgn3-pl
  • SEQ ID Nos: 1403 to 1413 SARS-CoV-2-orflab-rgn4-p2
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination consists of 11 or 12 siRNAs of different sequences, wherein the antisense strand of each of the 11 or 12 siRNAs has a sequence selected from the following groups:
  • SEQ ID Nos: 1368 to 1379 SARS-CoV-2-orflab-rgn2-pl
  • SEQ ID Nos: 1391 to 1402 SARS-CoV-2-orflab-rgn4-pl
  • SEQ ID Nos: 1425 to 1436 SARS-CoV-2-orflab-rgn6-pl
  • SEQ ID Nos: 1461 to 1472 SARS-CoV-2-orflab-rgn7-pl
  • SEQ ID Nos: 1473 to 1484 SARS-CoV-2-orflab-rgn7-p2
  • SEQ ID Nos: 1485 to 1496 SARS-CoV-2-orflab-rgn7-p3
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination comprises at least 8, 9 or 10 siRNAs of different sequences, wherein the antisense strand of each of the 8, 9 or 10 siRNAs has a sequence selected from the following groups:
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination comprises 9 siRNAs of different sequences.
  • the siRNA combination comprises 10 siRNAs of different sequences.
  • the siRNA combination comprises at least 12, 14, 16 or 18 siRNAs of different sequences, wherein the antisense strand of each of the 12, 14, 16 or 18 siRNAs has a sequence selected from the following groups:
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination comprises at least 12 siRNAs of different sequences.
  • the siRNA combination comprises at least 16 siRNAs of different sequences.
  • the siRNA combination comprises at least 18 siRNAs of different sequences.
  • the siRNA combination consists of 8, 9 or 10 siRNAs of different sequences, wherein the antisense strand of each of the 8, 9 or 10 siRNAs has a sequence selected from the following groups: (a) SEQ ID Nos: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847 (Cov-best-pl);
  • each of the antisense strand sequences is selected from the same group.
  • the siRNA combination consists of 10 siRNAs of different sequences.
  • the siRNA combination comprises at least 17, 18, 19 or 20 siRNAs of different sequences, wherein the antisense strand of each of the 17, 18, 19 or 20 siRNAs has a sequence selected from SEQ ID Nos: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729 (Cov-best- pl+p2).
  • the siRNA combination comprises 19 siRNAs of different sequences.
  • the siRNA combination comprises 20 siRNAs of different sequences.
  • the siRNA combination consists of 17, 18, 19 or 20 siRNAs of different sequences, wherein the antisense strand of each of the 17, 18, 19 or 20 siRNAs has a sequence selected from SEQ ID Nos: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729 (Cov-best- pl+p2).
  • the siRNA combination consists of 20 siRNAs of different sequences.
  • the antisense strand sequences are independently at least about 75% identical to the corresponding sequence. In one embodiment, each sequence is independently at least about 80% identical to the corresponding sequence. In one embodiment, each sequence is independently at least about 85% identical to the corresponding sequence. In one embodiment, each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, each sequence is independently at least about 98% identical to the corresponding sequence. It needs to be understood that each siRNA of the combination contains an antisense sequence as described above and a sense sequence that is chosen to be complementary to the antisense sequence.
  • the sense sequence must not be perfectly complementary but can contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides.
  • the sense strand of the siRNA contains 1 or 2 inserted, substituted, deleted and/or mismatched nucleotides.
  • the sense strand of the siRNA contains 1 inserted, substituted, deleted and/or mismatched nucleotide.
  • each antisense sequence which is complementary to a sequence within the target mRNA must not be perfectly complementary to the target mRNA but can, independently from the other antisense sequences within the combination of siRNAs, contain a certain number of inserted, substituted, deleted and/or mismatched nucleotides, e.g. up to 3, up to 2, or 1 inserted, substituted, deleted and/or mismatched nucleotide(s).
  • the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 1 to 427, wherein each sequence is at least about 75% identical to a sequence of SEQ ID NOs: 1 to 427. In one embodiment, the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 1 to 427, wherein each sequence is at least about 80% identical to a sequence of SEQ ID NOs: 1 to 427. In one embodiment, the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 1 to 427, wherein each sequence is at least about 85% identical to a sequence of SEQ ID NOs: 1 to 427.
  • the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 1 to 427, wherein each sequence is at least about 90% identical to a sequence of SEQ ID NOs: 1 to 427. In one embodiment, the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 1 to 427, wherein each sequence is at least about 95% identical to a sequence of SEQ ID NOs: 1 to 427. In one embodiment, the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 1 to 427, wherein each sequence is at least about 98% identical to a sequence of SEQ ID NOs: 1 to 427. In one embodiment, the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 1 to 427.
  • the siRNAs are directed to the Orflab polyprotein transcript.
  • the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 173 to 322; wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 173 to 322; wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 173 to 322; wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 173 to 322; wherein each sequence is independently at least about 90% identical to the corresponding sequence. In another preferred embodiment, the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 173 to 322; wherein each sequence is independently at least about 95% identical to the corresponding sequence. In another preferred embodiment, the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 173 to 322; wherein each sequence is independently at least about 98% identical to the corresponding sequence. In another preferred embodiment, the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 173 to 322.
  • the siRNAs are directed to the nucleocapsid protein transcript.
  • the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 43 to 87, wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 43 to 87, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 43 to 87, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 43 to 87, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In another preferred embodiment, the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 43 to 87, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In another preferred embodiment, the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 43 to 87, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In another preferred embodiment, the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 43 to 87.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 73 to 87 (siRNA combination SARS-CoV-2-N-p3 according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 73 to 87, wherein each sequence is independently at least about 80% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 73 to 87, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 73 to 87, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 73 to 87, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 73 to 87, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 73 to 87.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 218 to 232 (siRNA combination SARS-CoV-2-orflab-p3 according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 218 to 232, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 218 to 232, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequence SEQ ID Nos: 218 to 232, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequence SEQ ID Nos: 218 to 232, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequence SEQ ID Nos: 218 to 232, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequence SEQ ID Nos: 218 to 232.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 263 to 277 (siRNA combination SARS-CoV-2-orflab-p6 according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 263 to 277, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 263 to 277, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 263 to 277, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 263 to 277, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 263 to 277, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 263 to 277.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 203 to 217 (siRNA combination SARS-CoV-2-orflab-p2 according to Table 1), wherein each siRNA is independently at least about 75% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 203 to 217, wherein each siRNA is independently at least about 80% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 203 to 217, wherein each siRNA is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least SEQ ID Nos: 203 to 217, wherein each siRNA is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 203 to 217, wherein each siRNA is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 203 to 217, wherein each siRNA is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 203 to 217.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 293 to 307 (siRNA combination SARS-CoV-2-orflab-p8 according to Table 1). In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 58 to 72 (siRNA combination SARS-CoV-2-N-p2 according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 58 to 72, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 58 to 72, wherein each sequence is independently at least about 85% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 58 to 72, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 58 to 72, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 58 to 72, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 58 to 72.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 173 to 187 (siRNA combination SARS-CoV-2-orflab-pl according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 173 to 187, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 173 to 187, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 173 to 187, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 173 to 187, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 173 to 187, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 173 to 187.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 278 to 292 (siRNA combination SARS-CoV-2-orflab-p7 according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 278 to 292, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 278 to 292, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 278 to 292, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 278 to 292, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 278 to 292, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 278 to 292.
  • the combination of siRNAs comprises at least SEQ ID Nos: 308 to 322 (siRNA combination SARS-CoV-2-orflab-p9 according to Table 1). In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 163 to 172 (siRNA combination SARS-CoV-2-orflO according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 163 to 172, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 163 to 172, wherein each sequence is independently at least about 85% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 163 to 172, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 163 to 172, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 163 to 172, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 163 to 172.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 188 to 202 (siRNA combination SARS-CoV-2-orflab-plO according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 188 to 202, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 188 to 202, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 188 to 202, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 188 to 202, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 188 to 202, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 188 to 202.
  • the combination of siRNAs comprises at least SEQ ID Nos: 1107 to 1118 (siRNA combination SARS-CoV-2-N-rgnl-p2 according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1119 to 1130 (siRNA combination SARS-CoV-2-N-rgn2-pl according to Table 1).
  • the combination of siRNAs comprises at least SEQ ID Nos: 1131 to 1142 (siRNA combination SARS-CoV-2-orflab-rgnl-pl according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1143 to 1154 (siRNA combination SARS-CoV-2-orflab-rgnl-p2 according to Table
  • the combination of siRNAs comprises at least SEQ ID Nos: 1155 to 1166 (siRNA combination SARS-CoV-2-orflab-rgn2-pl according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1167 to 1177 (siRNA combination SARS-CoV-2-orflab-rgn3-pl according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1178 to 1189 (siRNA combination SARS-CoV-2-orflab-rgn4-pl according to Table 1).
  • the combination of siRNAs comprises at least SEQ ID Nos: 1190 to 1200 (siRNA combination SARS-CoV-2-orflab-rgn4-p2 according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1201 to 1211 (siRNA combination SARS-CoV-2-orflab-rgn5-pl according to Table
  • the combination of siRNAs comprises at least SEQ ID Nos: 1212 to 1223 (siRNA combination SARS-CoV-2-orflab-rgn6-pl according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1224 to 1235 (siRNA combination SARS-CoV-2-orflab-rgn6-p2 according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos:
  • the combination of siRNAs comprises at least SEQ ID Nos: 1248 to 1259 (siRNA combination SARS-CoV-2-orflab-rgn7-pl according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1260 to 1271 (siRNA combination SARS-CoV-2-orflab-rgn7-p2 according to Table
  • the combination of siRNAs comprises at least SEQ ID Nos: 1272 to 1283 (siRNA combination SARS-CoV-2-orflab-rgn7-p3 according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 1284 to 1295 (siRNA combination SARS-CoV-2-orflab-rgn7-p4 according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos:
  • the combination of siRNAs comprises at least SEQ ID Nos: 63, 299, 272, 302, 295, 179, 298, 268, 82, 300 (siRNA combination Cov-best-pl according to Table 1). In one embodiment, the combination of siRNAs comprises at least SEQ ID Nos: 177, 290, 271, 185, 76, 187, 81, 65, 301, 182 (siRNA combination Cov-best-p2 according to Table 1).
  • the combination of siRNAs comprises at least SEQ ID Nos: 307, 293, 263, 181, 86, 303, 275, 87, 280, 276 (siRNA combination Cov-best-p3 according to Table 1).
  • each sequence of the above described pools SARS-CoV-2-N- rgnl-p2, SARS-CoV-2-N-rgn2-pl, SARS-CoV-2-orflab-rgnl-pl, SARS-CoV-2- orf 1 ab-rgn 1 -p2, S ARS-CoV-2-orf 1 ab-rgn2-p 1 , SARS-CoV-2-orf 1 ab-rgn3 -p 1 ,
  • SARS-CoV-2-orf 1 ab-rgn4-p 1 SARS-CoV-2-orf 1 ab-rgn4-p2 S ARS-CoV-2-orf 1 ab- rgn5-pl SARS-CoV-2-orflab-rgn6-pl SARS-CoV-2-orflab-rgn6-p2 SARS-CoV-2- orflab-rgn6-p3, SARS-CoV-2-orflab-rgn7-pl, SARS-CoV-2-orflab-rgn7-p2, SARS-CoV-2-orflab-rgn7-p3, SARS-CoV-2-orflab-rgn7-p4, SARS-CoV-2-orflab- rgn7-p5, cov-best-pl, cov-best-p2, cov-best-p3, cov-best-pl+p2+p3, as mentioned in Table 1, is independently at least about 75%
  • each sequence is independently at least about 80% identical to the corresponding sequence. In one embodiment, each sequence is independently at least about 85% identical to the corresponding sequence. In one embodiment, each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, each sequence is independently at least about 98% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 63, 299, 272, 302, 295, 179, 298, 268, 82, 300, 177, 290, 271, 185, 76, 187, 81, 65, 301, 182 (siRNA combination Cov-best-pl +p2 according to Table 1), wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 63, 299, 272, 302, 295, 179, 298, 268, 82, 300, 177, 290, 271, 185, 76, 187, 81, 65, 301, 182, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 63, 299, 272, 302, 295, 179, 298, 268, 82, 300, 177, 290, 271, 185, 76, 187, 81, 65, 301, 182, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 63, 299, 272, 302, 295, 179, 298, 268, 82, 300, 177, 290, 271, 185, 76, 187, 81, 65, 301, 182, wherein each sequence is independently at least about 90% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 63, 299, 272, 302, 295, 179, 298, 268, 82, 300, 177, 290, 271, 185, 76, 187, 81, 65, 301, 182, wherein each sequence is independently at least about 95% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 63, 299, 272, 302, 295, 179, 298, 268, 82, 300, 177, 290, 271, 185, 76, 187, 81, 65, 301, 182, wherein each sequence is independently at least about 98% identical to the corresponding sequence.
  • the combination of siRNAs comprises at least sense sequences SEQ ID Nos: 63, 299, 272, 302, 295, 179, 298, 268, 82, 300, 177, 290, 271, 185, 76, 187, 81, 65, 301, 182.
  • siRNAs based on antisense and sense sequences
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 974, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 962, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 962, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 962, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 548 to 950, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869 (orflab polyprotein transcript being the target), wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 720 to 869, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634 (nucleocapsid protein transcript being the target), wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 2 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can independently contain up to 1 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 590 to 634, wherein each sequence is at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences.
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 620 to 634 (siRNA combination SARS-CoV-2-N-p3), wherein each sequence is independently at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 620 to 634, wherein each sequence is independently at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 620 to 634, wherein each sequence is independently at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 620 to 634, wherein each sequence is independently at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 620 to 634, wherein each sequence is independently at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 620 to 634, wherein each sequence is independently at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 765 to 779 (siRNA combination SARS-CoV-2-orflab-p3), wherein each sequence is independently at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 765 to 779, wherein each sequence is independently at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 765 to 779, wherein each sequence is independently at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 765 to 779, wherein each sequence is independently at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 765 to 779, wherein each sequence is independently at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 765 to 779, wherein each sequence is independently at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 810 to 824 (siRNA combination SARS-CoV-2-orflab-p6), wherein each sequence is independently at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 810 to 824, wherein each sequence is independently at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 810 to 824, wherein each sequence is independently at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 810 to 824, wherein each sequence is independently at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 810 to 824, wherein each sequence is independently at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 810 to 824, wherein each sequence is independently at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 750 to 764 (siRNA combination SARS-CoV-2-orflab-p2), wherein each sequence is independently at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 750 to 764, wherein each sequence is independently at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 750 to 764, wherein each sequence is independently at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 750 to 764, wherein each sequence is independently at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 750 to 764, wherein each sequence is independently at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 750 to 764, wherein each sequence is independently at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 840 to 854 (siRNA combination SARS-CoV-2-orflab-p8), wherein each sequence is independently at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 840 to 854, wherein each sequence is independently at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 840 to 854, wherein each sequence is independently at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 840 to 854, wherein each sequence is independently at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 840 to 854, wherein each sequence is independently at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 840 to 854, wherein each sequence is independently at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 605 to 619 (siRNA combination SARS-CoV-2-N-p2), wherein each sequence is independently at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 605 to 619, wherein each sequence is independently at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 605 to 619, wherein each sequence is independently at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 605 to 619, wherein each sequence is independently at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 605 to 619, wherein each sequence is independently at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 605 to 619, wherein each sequence is independently at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 720 to 734 (siRNA combination SAR.S-CoV-2-orflab-pl), wherein each sequence is independently at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 720 to 734, wherein each sequence is independently at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 720 to 734, wherein each sequence is independently at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 720 to 734, wherein each sequence is independently at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 720 to 734, wherein each sequence is independently at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 720 to 734, wherein each sequence is independently at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 825 to 839 (siRNA combination SARS-CoV-2-orflab-p7), wherein each sequence is independently at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 825 to 839, wherein each sequence is independently at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 825 to 839, wherein each sequence is independently at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 825 to 839, wherein each sequence is independently at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 825 to 839, wherein each sequence is independently at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 825 to 839, wherein each sequence is independently at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 855 to 869 (siRNA combination SARS-CoV-2-orflab-p9), wherein each sequence is independently at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 855 to 869, wherein each sequence is independently at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 855 to 869, wherein each sequence is independently at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 855 to 869, wherein each sequence is independently at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 855 to 869, wherein each sequence is independently at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 855 to 869, wherein each sequence is independently at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 710 to 719 (siRNA combination SARS-CoV-2-orflO), wherein each sequence is independently at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 710 to 719, wherein each sequence is independently at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 710 to 719, wherein each sequence is independently at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 710 to 719, wherein each sequence is independently at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 710 to 719, wherein each sequence is independently at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 710 to 719, wherein each sequence is independently at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 735 to 749 (siRNA combination SARS-CoV-2-orflab-plO), wherein each sequence is independently at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 735 to 749, wherein each sequence is independently at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 735 to 749, wherein each sequence is independently at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 735 to 749, wherein each sequence is independently at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 735 to 749, wherein each sequence is independently at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 735 to 749, wherein each sequence is independently at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the siRNA combination comprises at least antisense sequences SEQ ID NOs: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729 (siRNA combination Cov-best-pl+p2), wherein each sequence is independently at least about 75% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729, wherein each sequence is independently at least about 80% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729, wherein each sequence is independently at least about 85% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729, wherein each sequence is independently at least about 90% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729, wherein each sequence is independently at least about 95% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • the combination of siRNAs comprises at least antisense sequences SEQ ID NOs: 610, 846, 819, 849, 842, 726, 845, 815, 629, 847, 724, 837, 818, 732, 623, 734, 628, 612, 848, 729, wherein each sequence is independently at least about 98% identical to the corresponding sequence; and wherein the sense sequences are complementary to said antisense sequences, and wherein each sense sequence can optionally and independently contain up to 3 inserted, substituted, deleted and/or mismatched nucleotides (relative to the antisense sequence).
  • siRNA sequences targeted to viral transcripts, sense and antisense sequences are given 5’ to 3’ siRNA sequences targeted to host factor transcripts
  • the siRNAs of the combination according to the invention are directed to one or more host factor transcripts.
  • the host factor transcripts are selected from host factor transcripts associated with lipid metabolism.
  • siRNA sequences targeted to host factor transcripts are summarized in Table 2 below. If it is referred to a certain SEQ ID No. in the following, the corresponding sequence is listed in Table 2.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 975 to 1094, wherein each sequence is independently at least about 75% identical to the corresponding sequence. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 975 to 1094, wherein each sequence is independently at least about 80% identical to the corresponding sequence. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 975 to 1094, wherein each sequence is independently at least about 85% identical the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 975 to 1094, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 975 to 1094, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 975 to 1094, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In one embodiment, the antisense sequences of the siRNAs are independently selected from SEQ ID NOs: 975 to 1094.
  • the siRNAs are directed to the CERS6 transcript.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1065 to 1094, wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1065 to 1094, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1065 to 1094, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1065 to 1094, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In another preferred embodiment, the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1065 to 1094, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In another preferred embodiment, the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1065 to 1094, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In another preferred embodiment, the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1065 to 1094.
  • the siRNAs are directed to the SMPD2 transcript.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1035 to 1064, wherein each sequence is independently at least about 75% identical to the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1035 to 1064, wherein each sequence is independently at least about 80% identical to the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1035 to 1064, wherein each sequence is independently at least about 85% identical to the corresponding sequence.
  • the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1035 to 1064, wherein each sequence is independently at least about 90% identical to the corresponding sequence. In another preferred embodiment, the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1035 to 1064, wherein each sequence is independently at least about 95% identical to the corresponding sequence. In another preferred embodiment, the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1035 to 1064, wherein each sequence is independently at least about 98% identical to the corresponding sequence. In another preferred embodiment, the antisense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 1035 to 1064. siRNAs based on sense sequences
  • the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 428 to 547, wherein each sequence is at least about 75% identical to the corresponding sequence. In one embodiment, the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 428 to 547, wherein each sequence is at least about 80% identical to the corresponding sequence. In one embodiment, the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 428 to 547, wherein each sequence is at least about 85% identical the corresponding sequence. In one embodiment, the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 428 to 547, wherein each sequence is at least about 90% identical to the corresponding sequence.
  • the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 428 to 547, wherein each sequence is at least about 95% identical to the corresponding sequence. In one embodiment, the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 428 to 547, wherein each sequence is at least about 98% identical to the corresponding sequence. In one embodiment, the sense sequences of the siRNAs are independently selected from SEQ ID NOs: 428 to 547. In a preferred embodiment, the siRNAs are directed to the CERS6 transcript transcript. Thus, in a preferred embodiment, the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 518 to 547.
  • the siRNAs are directed to the SMPD2 transcript.
  • the sense sequences of the siRNAs are independently selected from the group comprising SEQ ID NOs: 488 to 517.
  • siRNA sequences targeted to host factor transcripts, sense and antisense sequences are given 5’ to 3’ - Ill - siRNA delivery
  • a nucleic acid delivery system may be used to increase an intracellular delivery efficiency of siRNA.
  • the nucleic acid delivery system for delivering nucleic acid material into cells may include a viral vector, a non-viral vector, liposome, cationic polymer, a micelle, an emulsion, albumin, and solid lipid nanoparticles.
  • the non- viral vector may have high delivery efficiency and long retention time.
  • the viral vector may include a retroviral vector, an adenoviral vector, a vaccinia virus vector, an adeno-associated viral vector, and an oncolytic adenovirus vector.
  • the nonviral vector may include a plasmid.
  • lipid nanoparticles may be used.
  • the cationic polymer for delivering nucleic acid may include natural polymer such as chitosan, atelocollagen, cationic polypeptide, and synthetic polymer such as poly(L-lysine), linear or branched poly-ethylene imine (PEI), spermine modified, cyclodextrin-based polycation, and dendrimer.
  • a particularly preferred delivery system for delivering the siRNA combinations is albumin.
  • albumin siRNA delivery has been described in Joshi et al., 2020 “Albumin nanocarriers for pulmonary drug delivery: An attractive approach” and Mehta et al., 2019 “Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles”.
  • the lipid nanoparticles form nucleic acid-lipid particles with the siRNA.
  • the nucleic acid-lipid particles generally include a cationic lipid, a non-cationic lipid, a sterol, and a lipid for preventing coagulation of particles (for example, a PEG-lipid conjugate).
  • the nucleic acid-lipid particles have an extended cycle lifespan after they are i.v. injected and are accumulated at a remote position (for example, a position physically remote from an administration site) and thus are extremely beneficial for a systemic application.
  • the nucleic acids are resistant to destruction by nucleases in an aqueous solution.
  • the nucleic acid-lipid particles and a method of preparing the same are, for example, disclosed in US Patent Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410; and 6,815,432; and WO 96/40964.
  • the nucleic acid-lipid particles may also include one or more additional lipids and/or other components, for example, cholesterol.
  • the other lipids may be included in a liposome composition for various purposes, for example, a purpose of preventing oxidation of lipids or attaching a ligand onto a surface of a liposome. Any number of lipids may exist since the liposome composition may include amphipathic, neutral, cationic, and anionic lipids. Such lipids may be used alone or in combination.
  • the additional components that may be present in the nucleic acid-lipid particles include a bilayer stabilizing component, for example, a polyamide oligomer (for example, see US Patent No. 6,320,017), a peptide, a protein, a detergent, and lipid derivatives, for example, PEG conjugated to phosphatidylethanolamine, and PEG conjugated to ceramide (see US Patent No. 5,885,613).
  • the nucleic acid-lipid particles may include at least one second aminolipid or cationic lipid, a neutral lipid, a sterol, and a lipid selected to reduce aggregation of lipid particles during formation in order to contribute to structural stabilization of particles which prevent charge- induced aggregation during the formation.
  • the nucleic acid-lipid particles may be prepared using an extrusion method or an in line mixing method.
  • the extrusion method (also referred to as a batch process) is a method of preparing a void liposome (e.g., having no nucleic acids) in advance and adding nucleic acids to the void liposome, which is disclosed in US Patent Nos. 5,008,050; 4,927,637; and 4,737,323; and Biochim Biophys Acta. 1979 Oct 19; 557(l):9-23; Biochim Biophys Acta. 1980 Oct 2; 601(3):559-7; Biochim Biophys Acta. 1986 Jun 13; 858(1): 161-8; and Biochim. Biophys.
  • the in-line mixing method is a method of adding lipids and nucleic acids to a mixing chamber side by side.
  • the mixing chamber may be simply a T-connector, or any of other mixing chambers known in the related art.
  • Such methods are disclosed in US Patent Nos. 6,534,018 and 6,855,277; US Patent Publication No 2007-0042031, and Pharmaceuticals Research, Vol. 22, No. 3, Mar. 2005, pp. 362-372.
  • a formulation may be prepared using any methods known in the related art.
  • the lipid-siRNA nanoparticles may be spontaneously formed during mixing.
  • the resulting nanoparticles mixture may be extruded through a polycarbonate membrane (for example, having a cut-off size of 200 nm or 100 nm).
  • siRNAs for efficient delivery to target tissue, the combination of siRNAs (or siRNA pools) according to the invention may be incorporated into nanoparticles, which can enter cells by endocytosis and reach the cytoplasm by endosome escape.
  • Nanoparticles can be formed by a broad range of natural or synthetic molecules as lipids, proteins (e.g. albumin) or polymers.
  • incorporation into microparticles with aerodynamic diameters between 1 and 5 pm is performed.
  • the matrices of these microparticles comprise excipients such as mannitol and trehalose which readily dissolve upon impact on lung lining fluid to release their nano-sized cargo.
  • a method to produce such nano-in-microparticles is spray drying, a method well established in chemical and pharmaceutical industry, see also Keil et al., “Impact of Crystalline and Amorphous Matrices on Successful Spray Drying of siRNA Polyplexes for Inhalation of Nano-in-Microparticles”, 2021. Chemical modifications
  • the siRNA may be chemically modified to enhance activity (e.g., stability, efficacy, and specificity), cellular distribution or cellular uptake, or other properties of the siRNA.
  • the siRNAs disclosed herein may be synthesized and/or modified by methods well established in the art.
  • Various embodiments of the siRNA may comprise at least one modified nucleotide (such as, e.g., by chemically modification, conjugation, or substitution) with any suitable group for improving the properties of the siRNA. It is unnecessary for all positions in a given siRNA to be uniformly modified. In some embodiment, more than one modifications may be incorporated in a single siRNA or at a single nucleoside within a siRNA.
  • Exemplary modifications include, e.g., end modifications, e.g., 5’-end modifications (e.g., phosphorylation, conjugation, inverted linkages, etc.) or 3’ -end modifications (e.g., conjugation, DNA nucleotides, inverted linkages, etc.); base modifications, e.g., replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases; sugar modifications (e.g., at the T -position or 4’ -position) or replacement of the sugar; and/or backbone modifications, including modification or replacement of the phosphodiester linkages.
  • end modifications e.g., 5’-end modifications (e.g., phosphorylation, conjugation, inverted linkages, etc.) or 3’ -end modifications (e.g., conjugation, DNA nucleotides, inverted linkages, etc.)
  • base modifications e.g., replacement
  • Embodiments of siRNAs having modified backbones may include those that retain a phosphorus atom in the backbone and those do not.
  • Exemplary modifications on the phosphate backbones of the siRNA include, e.g., phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, alkyl phosphonates, and those having inverted polarity wherein the adjacent pairs of nucleotides are linked 3’-5’ to 5’-3’ or 2’-5’ to 5’-2 ⁇
  • the sugar backbone of the siRNA may be replaced by, e.g., amide, morpholine, cyclobutyl, etc.
  • at least one strand of the siRNA may comprise a phosphorothioate modified phosphate backbone.
  • the phosphorothioate may comprise a P-S bond replacing a P-OH bond in the phosphate backbone.
  • any of the modified siRNAs described herein may also comprise one or more modified sugar moieties.
  • the modified sugar moiety may be a ribose or a deoxyribose.
  • the siRNA may comprise at least one modified nucleotide chosen from: e.g., a 2’-deoxy-2’-fluoro modified nucleotide, 2’-0-methyl modified nucleotide, 2’-deoxy-modified nucleotide, 2’ -0-(2-m ethoxy ethyl) nucleotide (2’-MOE-nucleotide), 2’-amino-modified nucleotide, 2’ -alkyl-modified nucleotide, and 2-SH-modified nucleotide.
  • modified sugar moieties also include, e.g., a locked nucleic acid (LNA), an open-loop or unlocked nucleic acid (UNA), and a peptide nucleic acid (PNA). Similar modifications may also be made at other positions on the siRNA, such as, e.g., at the 3’ position of the sugar on the 3’- terminal nucleotide, or at the 5’ position of the sugar on the 5’ -terminal nucleotide. In some embodiments, at least one strand of the siRNA may comprise a T -O-methyl modified nucleotide, i.e., a 2’-0-methyl modification on a ribose or a deoxyribose.
  • LNA locked nucleic acid
  • UPA open-loop or unlocked nucleic acid
  • PNA peptide nucleic acid
  • Similar modifications may also be made at other positions on the siRNA, such as, e.g., at the 3’ position of the sugar on the
  • At least one strand of the siRNA may comprise a 2’-deoxy-2’- fluoro modified nucleotide, i.e., a 2’-deoxy-2’-fluoro modification on a ribose or a deoxyribose.
  • at least one strand of the siRNA may comprise an LNA.
  • the LNA may comprise a cyclic structure formed between 2’-0 and 4’-C in a ribose or deoxyribose.
  • at least one strand of the siRNA may comprise an open-loop nucleic acid or UNA.
  • the open-loop nucleic acid or UNA may comprise a breakage between 2’-C and 3’-C of a ribose or deoxyribose.
  • at least one strand of the siRNA may comprise a PNA.
  • the PNA may comprise an amide containing backbone replacing the sugar backbone of a nucleotide.
  • siRNAs described herein may comprise a nucleobase (or base) modification.
  • nucleobase or base
  • "unmodified” or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).
  • Modified nucleobases include other synthetic and natural nucleobases, such as, e.g., 5-methylcytosine (5-me-C), 5 -hydroxymethyl cytosine, 5- acetylenyl uracil, 5-ethynyluracil, 5-propynyl uracil, xanthine, hypoxanthine, 2- aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2- thiouracil, 5-halouracil, 5-propynyl uracil, 6-azo cytosine, 5-uracil (pseudouracil), indole, 8-halo, 8-amino and other 8-modified adenines and guanines.
  • nucleobases such as, e.g., 5-methylcytosine (5-me-C), 5 -hydroxymethyl cytosine, 5- acetylenyl uracil, 5-ethyn
  • At least one strand of the siRNA may comprise an indole modification. In some embodiments, at least one strand of the siRNA may comprise a 5- methylcytosine modification. In some embodiments, at least one strand of the siRNA may comprise a 5-ethynyluracil modification.
  • Exemplary modifications of the siRNAs described herein also include linking the siRNA to one or more moieties or conjugates, which may enhance the activity of cellular uptake or targeting, or improve the half-life of the siRNA.
  • moieties may include but are not limited to lipid moieties (such as, e.g., cholesteryl derivative, phospholipid, aliphatic chain), peptides, nanoparticle, markers (such as, e.g.
  • cyanine fluorescent dye e.g., Cy3 or Cy5
  • polymers such as, e.g., polyamine or polyethylene glycol chain
  • sugars such as, e.g., galactosyl derivative
  • antibodies biotin, cholic acid, ligand, thiol
  • vitamin such as, e.g., vitamin E
  • NH 2 , phosphate, and folate The conjugates may be linked to the siRNA at the 5’ -end, 3’ -end, or both ends, or internally.
  • at least one strand of the siRNA may comprise a terminal nucleotide linked to a cholesteryl derivative.
  • the cholesteryl derivative is cholesterol.
  • At least one strand of the siRNA may comprise a terminal nucleotide linked to a galactosyl derivative.
  • the galactosyl derivative is galactose.
  • at least one strand of the siRNA may comprise one or more N-acetylgalactosamine (GalNAc) moieties.
  • the GalNac moiety is a monovalent GalNAc moiety, a bivalent GalNAc moiety, a trivalent GalNAc moiety, or a tetravalent GalNAc moiety.
  • at least one strand of the siRNA may comprise a terminal nucleotide linked to a peptide.
  • the peptide comprises the amino acid sequence N’-Arg-Gly-Asp-C’, i.e., an RGD peptide.
  • at least one strand of the siRNA may comprise a terminal nucleotide linked to a fluorescent marker.
  • the fluorescent marker is cyanine marker.
  • at least one strand of the siRNA may comprise a terminal nucleotide linked to a biotin molecule.
  • at least one strand of the siRNA may comprise a phosphorylated terminal nucleotide.
  • Various embodiments of the siRNA may comprise any combination of one or more modifications disclosed herein or known in the art.
  • At least one strand of the siRNA may comprise at least one chemical modification chosen from: (a) a phosphorothioate modified phosphate backbone; (b) a 2’-0-methyl modification in a ribose or deoxyribose; (c) a 2’-deoxy-2’-fluoro modification in a ribose or deoxyribose; (d) an LNA; (e) an open-loop nucleic acid or (UNA); (f) an indole modification; (g) a 5-methylcytosine; (h) a 5’-ethynyluracil; (i) a terminal nucleotide linked to a cholesteryl derivative (such as, e.g., cholesterol); (j) a terminal nucleotide linked to a galactosyl derivative (such as, e.g., GalNAc); (k) a terminal nucleotide linked to a peptide (such as
  • the siRNAs of the invention can also be modified based on click chemistry.
  • Click chemistry describes pairs of functional groups that rapidly and selectively react (click) with each other in mild, aqueous conditions.
  • the method is routinely used in bioconjugation reactions, for instance to selectively substitute nucleotides at specific positions with suitable side groups as for instance lipids or sugars as GlcNAc.
  • nucleosides with reactive click groups as for instance uridine with alkyne and azides click groups may be enzymatically incorporated in RNA molecules using RNA polymerase T7.
  • RNA molecules containing click- modified nucleotides may selectively react with a second click partner containing for instance strained cyclooctynes groups.
  • Preferred click modified nucleosides reported to work with RNA polymerase T7 by Jena bioscience are 5-azido-C3-UTP and 5-ethynyl-UTP. Further click modified nucleosides include 5-azidomethyl-UTP, 5-azido-PEG4-UTP, DBCO-PEG4-UTP, DBCO-PEG4-UTP, DBCO-PEG4-UTP, DBCO-PEG4-UTP and DBCO-PEG4-UTP.
  • Click chemistry is described inter alia in https://www.jenabioscience.com/images/741d0cd7d0/20140306_Click_Chemistry_B ackground_information_pdf_creator.pdf.
  • composition comprising the siRNA combinations
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a siRNA combination as described above in the first aspect.
  • the pharmaceutical composition optionally comprises a pharmaceutically acceptable carrier, diluent, or excipient.
  • the siRNAs may be present, for example, in an equimolar ratio. Two or more combined siRNAs may be used together or sequentially.
  • “Pharmaceutically acceptable carrier, diluent or excipient” refers to any of the standard pharmaceutical carriers, diluents, buffers, and excipients, such as, e.g., a phosphate buffered saline (PBS) solution, 5% aqueous solution of dextrose, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents and/or adjuvants.
  • PBS phosphate buffered saline
  • emulsions such as an oil/water or water/oil emulsion
  • Suitable pharmaceutical carriers, diluents or excipients and formulations are known in the art. Proper pharmaceutical carriers, diluents, or excipients may be selected depending upon the intended mode of administration of the active agent.
  • the pharmaceutical compositions may be administered by methods known in the art or disclosed herein.
  • the pharmaceutical compositions may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated.
  • Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer, intratracheal, intranasal), epidermal, and transdermal, spinal, oral, or parenteral.
  • the preferred administration is inhalative, i.e. by inhalation.
  • the pharmaceutical composition may be delivered to cells by a carrier chosen from a cationic liposome, chitosan nanoparticle, peptide, and polymer.
  • a "pharmaceutical acceptable carrier” or “excipient” refers to a pharmaceutically acceptable solvent, suspending agent, or any other pharmacologically inert vehicle for delivering one or more nucleic acids to a subject.
  • the excipient can be liquid or solid and can be selected, according to the planned manner of administration, to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition.
  • Exemplary pharmaceutical carriers include, e.g., binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, com starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).
  • binding agents e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxy
  • Suitable pharmaceutically acceptable carriers include, e.g., water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.
  • the pharmaceutical compositions may be formulated into any of many possible dosage forms, such as, e.g., tablets, capsules, gel capsules, powders, or granules.
  • the pharmaceutical compositions may also be formulated as solutions, suspensions, emulsions, or mixed media. In some embodiments, the pharmaceutical compositions may be formulated as a solution.
  • the siRNA may be administered in an unbuffered solution, such as, e.g., in saline or in water.
  • the siRNA may also be administered in a suitable buffer solution.
  • the buffer solution may comprise acetate, citrate, prolamine, carbonate, or phosphate, or any combination thereof.
  • the buffer solution may be phosphate buffered saline (PBS). The pH and osmolality of the buffer solution containing the siRNA can be adjusted to be suitable for administering to a subject.
  • the pharmaceutical compositions may also be formulated as suspensions in aqueous, non-aqueous, or mixed media.
  • Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran.
  • the suspension may also contain stabilizers.
  • the pharmaceutical compositions may also be formulated as emulsions.
  • exemplary emulsions include heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 mm in diameter.
  • Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in either the aqueous phase, the oily phase, or itself as a separate phase.
  • Microemulsions are also included as an embodiment of the present disclosure.
  • the pharmaceutical compositions may also be formulated as liposomal formulations.
  • liposome refers to a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior that contains the composition to be delivered. Cationic liposomes are positively charged lipo- somes which are believed to interact with negatively charged nucleic acid molecules, e.g., DNA molecules, to form a stable complex. Liposomes that are pH-sensitive or negatively-charged are believed to entrap DNA rather than complex with it.
  • Liposomes can be used to deliver the nucleic acid molecules described herein to cells.
  • Liposomes also include "sterically stabilized" liposomes, which may one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids.
  • sterically stabilized liposomes include those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic oligomers, such as a polyethylene glycol (PEG) moiety.
  • PEG polyethylene glycol
  • the pharmaceutical compositions described herein may also include surfactants.
  • the pharmaceutical compositions may also employ various penetration enhancers to effect the efficient delivery of nucleic acids.
  • penetration enhancers may also enhance the permeability of lipophilic drugs.
  • Exemplary penetration enhancers include surfactants, fatty acids, bile salts, chelating agents, and non-chelating non- surfactants.
  • the silencing of coronavirus genes and/or host factor genes by the siRNA combination of the present invention may remarkably reduce or eliminate SARS-CoV-2 infection, and therefore treat coronavirus disease, preferably coronavirus 2019 disease.
  • the siRNA combination according to one embodiment of the present invention may be used as a coronavirus disease, preferably coronavirus 2019 disease, therapeutic agent, and thus the present invention provides a composition for use in the treatment of coronavirus disease, preferably coronavirus 2019 disease, comprising the siRNA combination.
  • kits comprising the siRNA combinations
  • the present invention relates to a kit comprising the siRNA combination as described in the first aspect.
  • FIGURE LEGENDS
  • siPOOLs covering all transcripts of SARS-CoV-2, were tested in multiple independent experiments.
  • siPOOLs targeting human ACE2 and TMPRSS2 were used as positive controls.
  • a siPOOL consisting of non-targting siRNAs (negl), transfection reagent only (mock), absence of any treatment (untreated) and a siPOOL targeting human KIF11 (KIF11) were used as negative controls.
  • Non-infected (uninfected) cells were used to monitor the background of the assay.
  • Human Caco2 cells (2 experiments) and
  • African Green Monkey Kidney Vero cells (5 experiments) were infected with multiple titers of SARS-CoV-2 24h after siPOOL transfection and incubated for 24h or 48h. Viral infection was determined with a microscopy based assay, quantifying the total cells number by Hoechst stained cell nuclei and SARS-CoV-2 infected cells with a specific antibody detecting the viral N-protein. Infection rate is indicated as percentage of infected cells, normalized to the negative control siPOOL (negl). Each bar end error represents the average and standard deviation of triplicate mean values from 3 to 7 independent experiments. siPOOLs targeting different regions of the vims show large differences in antiviral activity.
  • Viral infection was determined with a microscopy-based assay, quantifying the total cell number by Hoechst stained cell nuclei and SARS-CoV-2 infected cells with a specific antibody detecting the viral N-protein. Infection rate is indicated as percentage of infected cells, normalized to the negative control siPOOL (negl). Each bar represents the normalized average and standard deviation of triplicate mean values from 2 experiments.
  • Figure 2 Screening results from all SARS-CoV-2 siPOOLs in list format, indicating numerical values for infection rate and cell count. The same experimental data was used as in figure la. Normalized mean and standard deviation are indicated for infection rate (% infected, SD% infected) and cell count (% cell count, SD % cell count). siPOOLs are ranked by the strength of the antiviral effect showing the strongest siPOOL (SARS-CoV-2-N-p3) on top. siPOOLs reducing infection rate below 15% are marked with a light grey star. siPOOLs reducing cell number by more than 20% are marked with a dark grey star. The column “bullet graph” gives a graphical representation of antiviral activity (vertical line) and cell toxicity (horizontal bar).
  • Figure 3 (a-e) Detailed visualization of screening results arranged by siPOOLs and controls.
  • the figures are based on the same experimental data as Figure la and 2.
  • Each panel shows the results of one single SARS- CoV-2 siPOOl or control in up to 7 experiments as indicated below the bars: Experiment 1 and 2 in human Caco2 cells with 24h and 48h incubation post infection (24h, 48h), experiment 3 to 7 in African Green Monkey Kidney Vero cells (CoVir l to CoVir_5). Gaps indicate experiments where siPOOLs were omitted. Bars indicate the normalized mean infection rate of experimental triplicates in %. Normalized mean cell count is indicated as line. Y-axis indicates % normalized readout with the negative control siPOOL set to 100.
  • Figure 4 Screening results of antiviral siPOOLs and controls indicated as box plots. The figures are based on the same experimental data as figure la, 2 and 3a-e using individual replicate data points. Each box plot represents data of up to 7 experiments. Light grey box plots indicate normalized mean infection rate. Dark grey boxes indicate normalized mean cell count. X-axis labels show the siPOOL or control used (top), the readout (center) and the number of data points (bottom).
  • Figure 5 Representative fluorescence microscopy images of human Caco2 cells infected with SARS-CoV-2.
  • Cells were transfected with a siPOOL targeting the viral N-gen (left) and the negative control siPOOL (right). 24h post transfection cells were infected with SARS-CoV-2 and fixed 48h later. Cell nuclei were stained with Hoechst (blue). SARS-CoV-2 infection was detected with a monoclonal antibody recognizing the viral N-gene (orange). Infected cells appear as blue cell nuclei with orange surrounding cytoplasma. Images were acquired with an automated epifluorescence microscope using a 20x lense.
  • Figure 6A-F Deconvolution of highly active antiviral siPOOLs in individual siRNAs
  • Figure 7 New antiviral siPOOLs targeting sensitive regions of the viral genome
  • Figure 8 Optimized antiviral siPOOLs consisting of most active single siRNAs from deconvolution of best siPOOLs
  • Figure 10 Time course of planned in vivo study in hamsters, delivering an antiviral lead siPOOL to nose and lung.
  • an element means one element or more than one element.
  • a group is defined to comprise at least a certain number of embodiments, this is also to be understood to disclose a group which preferably consists only of these embodiments.
  • a group is defined to comprise at least a certain number of sequences, this is also to be understood to disclose a group which preferably consists only of these sequences.
  • the term “about” means a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that varies by as much as 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
  • the term “about” in the context of the present invention denotes an interval of accuracy that the person skilled in the art will understand to still ensure the technical effect of the feature in question. In general, the term “about” is intended to modify a numerical value above and below the stated value by a variance of ⁇ 10%.
  • target sequence refers to a contiguous portion of the nucleotide sequence of an RNA molecule formed during the transcription of a target gene, including mRNA produced by RNA processing of a primary transcription product.
  • the target sequence may comprise 10-30 contiguous nucleotides of a SARS-CoV-2 and/or host factor mRNA, such as, e.g., 10-25 or 15-20 contiguous nucleotides of the mRNA.
  • the target sequence may comprise 11, 13, 15, 17, 19, 21, 23, 25, or 27 contiguous nucleotides of the mRNA.
  • the target sequence may comprise 19 contiguous nucleotides of the mRNA.
  • host factor describes a gene of the host (e.g. a mammal, preferably a human), which when silenced via RNAi, leads to reduced or eliminated viral infection (e.g. SARS-CoV-2 infection) and therefore, reduced or eliminated symptoms of coronavirus disease, preferably, coronavirus 2019 disease.
  • viral infection e.g. SARS-CoV-2 infection
  • coronavirus 2019 disease e.g. coronavirus 2019 disease.
  • nucleic acid can hybridize via hydrogen bond and form a duplex structure with another nucleic acid sequence under certain conditions. Such conditions may include, e.g., stringent conditions.
  • stringent conditions for hybridization refers to conditions under which a nucleic acid having complementarity to a target sequence predominantly hybridizes with the target sequence, and substantially does not hybridize to non-target sequences. Stringent conditions are sequence-dependent and vary depending on a number of factors. For example, the longer the sequence, the higher the temperature at which the sequence may hybridize to its target sequence. The skilled person will be able to determine the set of conditions most appropriate for a test of complementarity of two sequences in accordance with the ultimate application of the hybridized nucleotides.
  • the hybridization may be mediated by Watson-Crick base pairing or non-Watson- Crick base pairing, or base pairing formed with non-natural or modified nucleotides, as long as the above requirements with respect to their ability to hybridize are fulfilled.
  • Examples of non-Watson-Crick base pairing include G:U wobble or Hoogstein base pairing.
  • the hybridization between a nucleic acid molecule and its complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., RNAi activity.
  • the two nucleotide sequences are "fully complementary” with each other when all the contiguous nucleotides of the first nucleotide sequence base pairs with the same number of contiguous nucleotides of the second nucleotide sequence, e.g. with the first nucleotide sequence being the sense sequence and the second nucleotide sequence being the antisense sequence of the siRNA.
  • “Substantially complementary” means that the two sequences may be fully complementary, or they may form one or more mismatched base pairs upon hybridization, while retaining the ability to hybridize under the conditions most relevant to their ultimate application. In some embodiments, the two sequences form no more than 6 mismatches upon hybridization.
  • the two sequences may form no more than 4, 3, 2 or 1 mismatch.
  • two sequences are designed to form one or more single-stranded nucleotide overhangs upon hybridization, such overhangs shall not be regarded as mismatches for determining complementarity.
  • one oligonucleotide having 19 nucleotides in length and another oligonucleotide having 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 19 nucleotides that is fully complementary to the shorter oligonucleotide may yet be referred to as "fully complementary" for the purposes of this disclosure.
  • sequence identity refers to the extent that a sequence is identical on a nucleotide-by-nucleotide basis over a window of comparison (i.e., the entire sequence of a reference sequence).
  • a “percentage identity” may be calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the full length of the reference sequence), and multiplying the result by 100 to yield the percentage of sequence identity.
  • the identical nucleic acid base e.g., A, T, C, G, U
  • sequence identity refers to the ratio of the number of identical nucleotides to the reference sequence when those identical sequences are compared with the entire sequence of the reference sequence. Sequence identity between chemically modified siRNA sequences is calculated by comparing the corresponding unmodified nucleotide sequences.
  • RNA sequences For example, if a single-stranded RNA has 15 nucleotides in length, including 14 contiguous or non-conti guous nucleotides identical to a reference RNA sequence having 19 nucleotides, the identity between the two RNA sequences is 74% (14nt/19nt). By way of another example, if a single-stranded RNA has 17 nucleotides in length, which are identical to a reference RNA sequence having 19 nucleotides, the identity between the two RNA sequences is 89% (17nt/19nt).
  • RNA sequence may be said to "contain" the short reference RNA sequence.
  • a reference sequence may be interrupted by insertions or deletions as well as with substitutions in calculating percentage identity.
  • G,” “C,” “A,” and “U” each stand for guanine, cytosine, adenine and uracil nucleotide bases, respectively.
  • T and “dT” are used interchangeably and refer to a deoxyribonucleotide of which the nucleobase contains thymine, such as, e.g., deoxyribothymine, 2’-deoxythymidine or thymidine.
  • nucleotide or "ribonucleotide” or “deoxyribonucleotide” refers to a natural nucleotide comprising a nucleobase, a sugar and at least one phosphate group (e.g., a phosphodiester linking group). These terms can also refer to a modified nucleotide, e.g., a chemically- modified nucleotide, or a surrogate replacement moiety. Guanine, cytosine, adenine, and uracil may be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety.
  • nucleotide comprising inosine as its base may base pair with nucleotides containing adenine, cytosine or uracil.
  • nucleotides containing uracil, guanine or adenine in the nucleotide sequences described herein may be replaced by a nucleotide containing, e.g., inosine.
  • cytosine anywhere in the nucleotide sequences described herein may be replaced with guanine or uracil.
  • nucleobase or “base” are used interchangeably to refer to a purine or pyrimidine base found in natural DNA or RNA (e.g., uracil, thymine, adenine, cytosine and guanine).
  • base e.g., uracil, thymine, adenine, cytosine and guanine.
  • the terms also include analogs or modified counterparts of these natural purines and pyrimidines, which may confer improved properties to the nucleic acid molecule.
  • siRNA refers to any nucleic acid molecule capable of inhibiting or down-regulating gene expression, e.g., by mediating sequence-specific degradation of an RNA transcript, e.g., an mRNA, through RNAi or gene silencing.
  • the siRNA can be a double-stranded polynucleotide molecule comprising self-complementary sense and antisense regions.
  • the antisense region comprises a nucleotide sequence that is complementary to the nucleotide sequence in a target nucleic acid molecule (e.g., an Orflab polyprotein transcript and/or the nucleocapsid protein transcript) or a portion thereof (e.g., a target sequence or a portion thereof), and the sense region comprises a nucleotide sequence corresponding to the target sequence or a portion thereof.
  • the siRNA can be assembled from two separate oligonucleotides and comprises a sense strand and an antisense strand, wherein the antisense and sense strands are complementary, i.e.
  • each strand comprises a nucleotide sequence that is complementary to a nucleotide sequence in the other strand such that the antisense strand and sense strand form a duplex or double-stranded structure.
  • the antisense strand comprises a nucleotide sequence that is complementary to a nucleotide sequence in a target nucleic acid molecule (e.g., an Orflab polyprotein transcript and/or the nucleocapsid protein transcript) or a portion thereof (e.g., a target sequence or a portion thereof), and the sense strand comprises a nucleotide sequence corresponding to the target sequence or a portion thereof.
  • a target nucleic acid molecule e.g., an Orflab polyprotein transcript and/or the nucleocapsid protein transcript
  • the sense strand comprises a nucleotide sequence corresponding to the target sequence or a portion thereof.
  • the siRNA can also be assembled from a single oligonucleotide, wherein the self-complementary sense and antisense regions of the siRNA are linked by a nucleotide based or non-nucleotide based linker(s).
  • the siRNA can be a polynucleotide having a duplex, asymmetric duplex, hairpin, or asymmetric hairpin secondary structure.
  • the siRNA can be a circular single-stranded polynucleotide having two or more loop structures and a stem comprising self-complementary sense and antisense regions.
  • the circular polynucleotide can be processed either in vivo or in vitro to generate an active siRNA molecule capable of mediating RNAi.
  • the siRNA can also comprise a single-stranded polynucleotide having nucleotide sequence complementary to a nucleotide sequence in a target nucleic acid molecule or a portion thereof (e.g., an Orflab polyprotein transcript and/or the nucleocapsid protein transcript), where such siRNA molecule does not require the presence within the siRNA molecule of a nucleotide sequence corresponding to the target sequence or a portion thereof.
  • the siRNA molecules need not be limited to those molecules containing only natural nucleotides, but further encompasses modified nucleotides and non-nucleotides.
  • the majority of nucleotides of each strand of an siRNA molecule are ribonucleotides, but as described in detail below and in the section “Chemical modifications”, each or both strands can also include one or more non-ribonucleotides, e.g., a deoxyribonucleotide, and/or a modified nucleotide, e.g., a chemically modified nucleotide.
  • the siRNA molecules may include chemical modifications at multiple nucleotides or multiple chemical modifications on a single nucleotide. Such modifications may include all types of modifications disclosed herein or known in the art.
  • modified nucleotide generally refers to a nucleotide, which contains a modification in the chemical structure of the base, sugar and/or phosphate of the unmodified (or natural) nucleotide as is generally known in the art.
  • RNA can also include other terms used to describe nucleic acid molecules capable of mediating sequence-specific RNAi, e.g., double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically-modified siRNA, and post-transcriptional gene silencing RNA (ptgsRNA).
  • dsRNA double-stranded RNA
  • miRNA micro-RNA
  • shRNA short hairpin RNA
  • RNAf'can include other terms used to describe sequence-specific RNAi, such as post-transcriptional gene silencing, gene silencing, translational inhibition, or epigenetics.
  • the siRNA may modulate, e.g., inhibit, the expression of Orflab polyprotein transcript and/or the nucleocapsid protein transcript in a cell, e.g. a cell in a culture or a cell within a subject, such as, e.g., a mammalian subject, e.g., a human.
  • nucleotide overhang refers to the unpaired nucleotide or nucleotides that protrude from the duplex structure of a double-stranded siRNA molecule when a 3’- end of one strand of the siRNA extends beyond the 5’ -end of the other strand, or vice versa.
  • Bount or “blunt end” means that no unpaired nucleotides exist at that end of a double-stranded siRNA molecule, i.e., no nucleotide overhang.
  • siRNAs described herein include double-stranded siRNAs with nucleotide overhangs at one end, i.e., siRNAs with one overhang and one blunt end, or with nucleotide overhangs at both ends.
  • the siRNAs described herein also include siRNA that is double- stranded over its entire length, i.e., no nucleotide overhang at either end of the molecule.
  • inhibitor means that the expression of the gene, or level of the mRNA molecules or equivalent RNA molecules encoding one or more proteins or protein subunits, or level or activity of one or more proteins or protein subunits, is reduced below that observed in the absence of the nucleic acid molecules (e.g., siRNA) described herein.
  • inhibition, down-regulation, reduction, silencing, blocking, or suppression with an siRNA molecule is below that level observed in the presence of an inactive or attenuated molecule.
  • inhibition, down-regulation, reduction, silencing, blocking, or suppression with an siRNA molecule is below that level observed in the presence of, for example, an siRNA molecule with a scrambled sequence or with mismatches (e.g., an siRNA molecule with a random non-specific sequence).
  • an siRNA molecule with a scrambled sequence or with mismatches e.g., an siRNA molecule with a random non-specific sequence.
  • a "subject" or a "subject in need thereof includes a mammalian subject such as a human subject.
  • a "therapeutically effective amount” or “effective amount” of a compound or composition refers to an amount effective in the prevention or treatment of a disorder for the treatment of which the compound or composition is effective.
  • the term includes the amount of an siRNA molecule that, when administered to a subject for treating coronavirus disease, preferably coronavirus 2019 disease, is sufficient to effect treatment of the disease, e.g., by diminishing, ameliorating, or maintaining the existing disease or one or more symptoms of the disease, or by inhibiting the progression of the disease.
  • the “therapeutically effective amounfor "effective amount” may vary depending on the combination of siRNAs, the route of administration, the disease and its severity, and the health, age, weight, family history, genetic makeup, stage of pathological processes, the types of preceding or concomitant treatments, if any, and other individual characteristics of the subject to be treated.
  • the term "treatment” includes treatment of a subject (e.g. a mammal, such as a human) or a cell to alter the current course of the subject or cell. Treatment includes, but is not limited to, administration of a pharmaceutical composition, and may be performed either prophylactically or subsequent to the initiation of a pathologic event or contact with an etiologic agent.
  • prophylactic treatments which can be directed to reducing the rate of progression of the disease or condition being treated, delaying the onset of that disease or condition, or reducing the severity of its onset.
  • Treatment does not necessarily indicate complete eradication, cure, or prevention of the disease or condition or the associated symptoms.
  • the term “treatment” may include relieving, slowing, or reversing the pathological processes or symptoms.
  • Coronaona disease 2019” or COVID-19 is a contagious disease caused by SARS-CoV- 2.
  • COVID-19 refers to a disease as defined in the current international classification of diseases (ICD-11, World Health Organisation, Version: 09/2020). More particularly, COVID-19 is used to denote the disease, diagnosed clinically, epidemiologically or otherwise, irrespective of whether laboratory testing is conclusive, inconclusive or not available.
  • Treating or preventing of COVID-19 may include treating or preventing at least one of lung fibrosis, interstitial pneumonia, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), aveolar damage, kidney injury, vasculopathy, cardiac injury, acute myocardial injury, chronic damage to the cardiovascular system, thrombosis and venous thromboembolism, in a patient with COVID-19.
  • lung fibrosis, interstitial pneumonia, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), kidney injury, such as proteinuria and acute kidney injury, and vasculopathy are triggered by COVID-19.
  • COVID19 is caused by SARS-CoV-2, also termed 2019-nCoV, which refers to severe acute respiratory syndrome coronavirus-2 firstly described by Zhu et ah, 2019 and variants thereof, e.g. without limitation variant B.l.1.7 (also known as 201/501 Y. VI, VOC 202012/01), B.1.351 (20H/501Y.V2) and PI, as defined by the Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (ICTV-CSG).
  • 2019-nCoV refers to severe acute respiratory syndrome coronavirus-2 firstly described by Zhu et ah, 2019 and variants thereof, e.g. without limitation variant B.l.1.7 (also known as 201/501 Y. VI, VOC 202012/01), B.1.351 (20H/501Y.V2) and PI, as defined by the Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (ICTV-CSG
  • SARS-CoV-2 is used to denote all variants of a virus, according to ICTV belonging to realm Riboviria, kingdom Orthomavirae, phylum Pisuviricota, class Pisoniviricetes, order Nidovirales, family Coronaviridae, genus Betacoronavirus, subgenus Sarbecovirus, species Severe acute respiratory syndrome- related coronavirus, strain Severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2).
  • ICTV belonging to realm Riboviria, kingdom Orthomavirae, phylum Pisuviricota, class Pisoniviricetes, order Nidovirales, family Coronaviridae, genus Betacoronavirus, subgenus Sarbecovirus, species Severe acute respiratory syndrome- related coronavirus, strain Severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2).
  • Example 1 siRNA transfection in different cell lines using siRNA combinations targeting SARS-CoV-2 or host factor transcripts
  • siRNA transfection mix was prepared with RNAiMax transfection reagent (Thermo Fisher) according to the supplier’s instructions and transferred to 96 well tissue culture plates (20 m ⁇ [3 nM siRNA] per well).
  • siRNA sequences correspond to the sequences as listed in tables 1 and 2 with the corresponding names and SEQ ID Nos.
  • cells were seeded (10 4 cells in 80m1 cell culture medium/well) and incubated at 37 °C and 5% C0 2. 48 hrs after transfection, the cells were infected by adding SARS-CoV-2 isolate 2019_nCoV Muc-IMB-1 (5xl0 3 plaque forming units in 100 m ⁇ cell culture medium / well). At 24 or 48h hrs post infection, the cells were fixed with 4% paraformaldehyde (30 min incubation at room temperature) and immunostained with a monoclonal antibody recognizing the viral nucleoprotein N (4E10A3A1 (RRID:AB_2833160) by standard indirect immunofluorescence protocols). Cell nuclei were stained with Hoechst 33342 (Sigma-Aldrich).
  • the stained cells were imaged with a Leica Thunder imaging system (lOx objective, 6 fields of view per well). Acquired image data sets were quantitatively analyzed with the image analysis software packages arivis Vision4D or CellProfiler. In both cases, cell nuclei were segmented and counted using the Hoechst DNA staining. As cells normally have one single cell nucleus, the number of cell nuclei was considered to be the number of cells. Staining intensity of the viral nucleoprotein in the vicinity of cell nuclei was used to determine viral infection of individual cells. Infection rate in the cell population was defined as the percentage of cells with perinuclear nucleoprotein staining above a given threshold.
  • siPOOL “negl” used for normalization is indicated in black and set to 100%.
  • additional controls were used in the screening experiments: “untreated”: cells without siPOOL or transfection reagent (light grey); “mock”: transfection reagent only (dark grey); “KIFll”: transfection control with siPOOL targeting human KIFll (grey), “unifected”: untreated cells that were not infected with the virus.
  • siPOOLs targeting human ACE2 and human TMPRSS2 were used as positive controls. As ACE2 and TMPRSS2 are not perfectly conserved between human and green monkey (Cercopithecus aethiops), silencing of Ace2 and Tmprss2 is expected to be less efficient.
  • Viral and host factor siPOOLs correspond to the remaining bars. Infection rates in negative control, KIFll and mock transfected cells as well as untreated cells were similar demonstrating the reproducibility of the assay. The infection rate calculated for uninfected controls indicates the background of the assay.
  • Example 2 Deconvolution of siRNA pools of 15 siRNAs into individual siRNAs and functional testing of antiviral activity in cell culture Materials and methods
  • siRNA transfection mix was prepared with RNAiMax transfection reagent (Thermo Fisher) according to the supplier’s instructions and transferred to 96 well tissue culture plates (20 m ⁇ per well).
  • siRNA sequences correspond to the sequences as listed in tables 1 and 2 with the corresponding names and SEQ ID Nos. Then, cells were seeded (10 4 cells/well in 80m1 cell culture medium/well) and incubated at 37 °C and 5% C02.
  • the stained cells were imaged with a Leica Thunder imaging system (lOx objective, 6 fields of view per well). Acquired image data sets were quantitatively analyzed with the image analysis software packages arivis Vision4D or CellProfiler. In both cases, cell nuclei were segmented and counted using the Hoechst DNA staining. As cells normally have one single cell nucleus, the number of cell nuclei was considered to be the number of cells. Staining intensity of the viral nucleoprotein in the vicinity of cell nuclei was used to determine viral infection of individual cells. Infection rate in the cell population was defined as the percentage of cells with perinuclear nucleoprotein staining above a given threshold.
  • a negative control siPOOL (“Neg”) with 30 non-targeting 30 siRNAs and mock transfected cells, treated with transfection reagent without siRNAs were present in 2 replicates on each 96well plate.
  • the antiviral siPOOL SAR.S-CoV-2-ORFlab-pl was used as positive control (“pos”).
  • Single siRNAs and positive controls were tested in two replicates, present on two identical experimental plates. Mean cell count and % infected cells of samples and controls were normalized to the mean of all 4 Neg replicates on the two replicate plates and indicated as percentage of the negative control.
  • antiviral siPOOLs SARS-CoV-2-N-pl, SARS-CoV-2-N-p2, SARS-CoV-2- ORFlab-pl, SARS-CoV-2-ORFlab-p6, SARS-CoV-2-ORFlab-p7 and -p8, were deconvoluted in their 15 individual siRNAs and assayed for antiviral activity and cell toxicity as described. No cell toxicity, obvious in strongly reduced cell count was observed for the controls or any of the individual siRNAs. Antiviral activity of the positive control siPOOL was strong with 14% and 6% remaining infection on the two experimental plate duplicates (pi -2 amd p3-4) as compared to the negative control.
  • siRNAs with strongest antiviral activity ranging from 1% to 25% % infected cells were selected to compose 3 optimized siPOOls with 10 siRNAs each.
  • the functional validation of these 3 siPOOLs cov-best-pl, cov-best-p2 and cov-best-p3 are described in examples 4 and 5.
  • Figures 6A to 6F show the data of each deconvoluted siPOOL in a separate figure.
  • Each bar represents the mean of 2 to 4 replicates, normalized to the plate mean of all Neg control samples. Names of single siRNAs or controls are indicated below each bar.
  • the negative control siPOOL “Neg” used for normalization is shown as 100, Two mean values are shown for the transfection reagent only control mock (“mock pi -2” and mock p3-4” )and the positive control pos (“pos pi -2” and pos p3-4”) representing the antiviral siPOOL SARS-CoV-2-ORFlab-pl. Blue bars indicate normalized cell count, representing cell viability. Orange bars indicate normalized percentage of infected cells.
  • Figure 6A shows 15 individual siRNAs, N-p2-si01 to N- p2-sil5 of siPOOL SARS-CoV-2_N-p2.
  • Figure 6B shows 15 individual siRNAs, N- p3-si01 to N-p3-sil5 of siPOOL SARS-CoV-2_N-p3.
  • Figure 6C shows 15 individual siRNAs, ORFlab-pl-siOl to ORFlab-pl-sil5 of siPOOL SARS-CoV-2-ORFlab - pi.
  • Figure 6D shows 15 individual siRNAs, ORFlab-p6-si01 to ORFlab-p6-sil5 of siPOOL SARS-CoV-2-ORFlab-p6.
  • Figure 6E shows 15 individual siRNAs, ORFlab-p7-si01 to ORFlab-p7-sil5 of siPOOL SARS-CoV-2-ORFlab -p7.
  • Figure 6F shows 15 individual siRNAs, ORFlab-p8-si01 to ORFlab-p8-sil5 of siPOOL SARS-CoV-2-ORFlab -p8.
  • siRNA pools covering the entire SARS-CoV-2 genome, 2 regions in the N-gene and 7 regions in the ORF- lab-gene were identified as highly sensitive to inhibition with siRNA molecules.
  • siPOOLs showed high to very high antiviral activity. 4 of the new 17 siPOOLs were more active than ORF-lab-pl, representing one of the most active pools of the first set of 30 antiviral siPOOLs used as positive control in this experiment.
  • the exceptionally high rate of strongly active, new siPOOLs designed for specific regions of the viral genome validates the finding that certain regions of the viral genome, namely the N-gene and ORFlab gene (or preferably, sections of the N-gene and certain parts of the ORFlab gene) are especially suitable for the silencing with siRNAs.
  • Figure 7 shows the data of the new antiviral siPOOLs and controls each bar representing the mean of 2 to 4 replicates, normalized to the plate mean of all Neg control samples. Names of new antiviral siPOOLs or controls are indicated below each bar.
  • the negative control siPOOL “Neg” used for normalization is shown as 100, The transfection reagent only control is termed “mock”.
  • the positive control “pos” represents the antiviral siPOOL SAR.S-CoV-2-ORF lab-pl. Blue bars indicate normalized cell count, representing cell viability. Orange bars indicate normalized percentage of infected cells.
  • Example 4 Testing of optimized siPOOLs, consisting of selected, highly active siRNAs.
  • siRNAs with strongest antiviral activity reducing viral infection to 1% to 25% infection were recombined to 3 new siPOOLs termed cov-best-pl, cov-best-p2 and cov-best-p3.
  • Cov-best -pi containing the 10 strongest siRNAs reducing viral infection to 1% to 8%
  • cov-best-p2 containing the second best set of siRNAs reducing viral infection to a range of 9% to 15%
  • cov-best-p3 containing the third best set of siRNAs, reducing viral infection to a range of 16% to 25%.
  • the new siPOOLs were tested individually as well as in combinations. For comparison, a set of other antiviral siPOOLs with varying antiviral activity was tested.
  • siPOOL or siPOOL combination was tested in 4 replicates.
  • the infection assay was identical to the protocol described in example 2.
  • single replicate values were first normalized to the plate mean of all Neg control samples. Next medians and standard deviations were calculated for each sample and control. Results
  • Cov-best-pl and cov-best-p2 siPOOLs show a similar, strong antiviral activity as the positive control Orf-lab-pl with a slight tendency to even higher efficiency.
  • Cov- best-p3 containing the weakest of the top 30 selected siRNAs shows a significantly lower antiviral activity.
  • Combinations of the siPOOls show intermediate phenotypes.
  • the positive control siPOOL (“pos”) Orflab-pl reducing viral infection only to an average of 30%, the experiment shows an overall lower efficiency and higher variability of the RNAi reagents which can be attributed to differences within the technical variability of the cell based assay.
  • Figure 8 shows the data of the new optimized antiviral siPOOLs and controls each bar representing the median of 4 replicates, normalized to the plate mean of all Neg control samples. Names of antiviral siPOOLs or controls are indicated below each bar.
  • the negative control siPOOL “Neg” used for normalization is shown as 100, The transfection reagent only control is termed “mock”.
  • the positive control “pos” represents the antiviral siPOOL SARS-CoV-2-ORFlab-pl. Blue bars indicate normalized cell count, representing cell viability. Orange bars indicate normalized percentage of infected cells.
  • siPOOLs SARS-CoV- 2-N-p3 (sown as “N-p3”), SARS-CoV-2-ORFlab-p2 (sown as “orflab-p2”), siPOOLs SARS-CoV-2-S-p3 (sown as “S-p3”), SARS-CoV-2-ORFlab-rgnl-p2 (sown as “orfl-rgnl-p2”), SARS-CoV-2-ORFlab-rgn7-p4 (sown as “orfl-rgn7-p4”), SARS-CoV-2-ORFlab-rgn6-p3 (sown as “orfl-rgn6-p3”) and SARS-CoV-2-ORF3a- p3 (sown as “orfia-pS”) are shown as comparison.
  • Example 5 Validation of lead siPOOLs for the in vivo testing in a hamster model and preclinical development
  • the optimized siPOOLs cov-best pi, cov-best p2 and cov-best p3 were combined and validated in two compositions to serve as lead siPOOLs for animal testing and preclinical development: cov-best pi and cov-best p2 (cov-best pl+p2) and cov-best pi, cov-best p2 and cov-best p3 (cov-best pl+p2+p3). Vero cells were transfected and infected in 96well plate format generally following the protocol described in example 2.
  • the negative control siPOOL “Neg” used for normalization is shown as 100, The transfection reagent only control is termed “mock”.
  • the positive control “pos” represents the antiviral siPOOL SARS-CoV-2- ORFlab-pl. Blue bars indicate normalized cell count, representing cell viability. Orange bars indicate normalized percentage of infected cells.
  • the lead siPOOL cov-best-pl+p2 consistig of the twenty single siRNAs with the strongest antiviral effect shown in example 2 and validated in examples 4 and 5 was produced in lpmol scale for testing in an animal model. 400nmol of the negative control “Neg” were produced as reference. Both siPOOLs were tested for interferon response, assessing the expression of the interferon response gene IFIT1. Both siPOOLs showed no increased expression as compared to mock transfected and non transfected samples indicating the absence of cell toxicity by interferon response.
  • the antiviral lead siPOOL and the negative control siPOOL will be formulated in lipid nanoparticle using 3 different lipid compositions, representing the current gold standard LNP formulation and two novel formulations with optimized properties for the delivery to airway epithelia in nose, trachea and lung.
  • the gold standard LNP formulation is considered to be the lipid composition of the LNPs used for the approached siRNA drug Onpattro /Patisiran and the currently used mRNA based SARS-CoV-2 vaccines developed by BionTech/Pfizer.
  • lipid nanoparticles entrapping siPOOLs are prepared by established rapid mixing protocols (https://onlinelibrary.wiley.com/doi/full/10.1002/smtd.201700375).
  • lipid mixtures in ethanol are mixed rapidly with siPOOLs dissolved in sodium acetate or sodium citrate buffer (pH 4).
  • Resulting LNP-siPOOLs formulations are dialyzed against physiological buffer (pH 7.4), sterile filtered, and concentrated.
  • LNP-siPOOLs size and polydispersity are determined by dynamic light scattering (DLS) measurement.
  • siPOOLs entrapment efficiency is assessed by Quant-iT Ribogreen RNA assay. Total lipid concentration is assessed by cholesterol quantification assay.
  • Figure 10 shows the time course of the ongoing in vivo study with 3 siRNA treatements 24h, 48h and 72h after infection applied to nose and lung.
  • a combination of siRNAs targeted to one or more severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transcripts and/or host factor transcripts wherein said combination of siRNAs comprises at least two siRNAs of different sequences and wherein each siRNA comprises an antisense strand and a sense strand.
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • each siRNA is independently 10 to 27 base pairs in length, preferably 15 to 27 base pairs in length and most preferably 17 to 23 base pairs in length. 4. The combination according to any of the preceding items, wherein the antisense strand of each siRNA is independently selected from SEQ ID NOs: 548 to 1094 and is independently at least 75% identical to the selected sequence.
  • siRNAs are directed to one or more SARS-CoV-2 transcripts selected from the group comprising the spike protein transcript, envelope protein transcript, nucleocapsid protein transcript, membrane protein transcript and/or Orflab polyprotein transcript; wherein preferably the siRNAs are directed to the Orflab polyprotein transcript and/or the nucleocapsid protein transcript.
  • each siRNA is independently selected from SEQ ID NOs: 548 to 974 and is independently at least 75% identical to the selected sequence.
  • each siRNA is independently selected from the group comprising SEQ ID NOs: 720 to 869 or wherein the antisense strand of each siRNA is independently selected from the group comprising SEQ ID NOs: 590 to 634.
  • each siRNA is independently selected from SEQ ID NOs: 975 to 1094 and is independently at least 75% identical to the selected sequence.
  • each siRNA optionally comprises 1-5 single-stranded nucleotides at its 3’ terminus, preferably 2 single-stranded nucleotides.
  • each siRNA optionally comprises a modification selected from (a) a phosphorothioate modification in the phosphate backbone;
  • a pharmaceutical composition comprising the combination of siRNAs according to any of 1 to 12.
  • a kit comprising the combination of siRNAs according to any one of 1 to 12.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des combinaisons d'ARNsi ciblant des transcrits de coronavirus (SRAS-CoV-2) et/ou des transcrits de facteur hôte. L'invention concerne en outre des combinaisons d'ARNsi et des compositions pharmaceutiques comprenant lesdites combinaisons d'ARNsi destinées à être utilisées dans le traitement et la prophylaxie d'infections à coronavirus, en particulier de la maladie de COVID-19.
EP22738426.0A 2021-06-25 2022-06-27 Combinaisons d'arnsi ciblant les transcrits du sras-cov-2 et/ou du facteur hôte Pending EP4359528A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21181809 2021-06-25
PCT/EP2022/067506 WO2022269097A1 (fr) 2021-06-25 2022-06-27 Combinaisons d'arnsi ciblant les transcrits du sras-cov-2 et/ou du facteur hôte

Publications (1)

Publication Number Publication Date
EP4359528A1 true EP4359528A1 (fr) 2024-05-01

Family

ID=76623988

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22738426.0A Pending EP4359528A1 (fr) 2021-06-25 2022-06-27 Combinaisons d'arnsi ciblant les transcrits du sras-cov-2 et/ou du facteur hôte

Country Status (2)

Country Link
EP (1) EP4359528A1 (fr)
WO (1) WO2022269097A1 (fr)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
AU723163B2 (en) 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
IL143104A (en) 1998-11-13 2005-09-25 Optime Therapeutics Inc Method and apparatus for liposome production
US9005654B2 (en) 2005-07-27 2015-04-14 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
WO2013160393A1 (fr) 2012-04-26 2013-10-31 Intana Bioscience Gmbh Groupes d'arnsi de haute complexité
KR20220097463A (ko) * 2019-11-07 2022-07-07 알리고스 테라퓨틱스 인코포레이티드 바이러스 분자 수준을 감소시키는 방법
CN111748557B (zh) * 2020-04-03 2022-03-11 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用

Also Published As

Publication number Publication date
WO2022269097A1 (fr) 2022-12-29

Similar Documents

Publication Publication Date Title
US11851658B2 (en) Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
US11773390B2 (en) Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNA
US11697812B2 (en) Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
Thomas et al. Non-viral siRNA delivery to the lung
US20070218122A1 (en) siRNA silencing of influenza virus gene expression
JP2009514877A (ja) ｓｉＲＮＡの送達媒体としてのペプチド−ダイザ基質ＲＮＡ抱合体
US9574243B2 (en) Compositions and methods for the treatment of influenza infection
US10036020B2 (en) Compositions and methods for inhibiting JC virus (JCV)
EP4183879A1 (fr) Oligonucléotide double brin et composition pour le traitement de la covid-19 le contenant
EP4359528A1 (fr) Combinaisons d'arnsi ciblant les transcrits du sras-cov-2 et/ou du facteur hôte
US20210348167A1 (en) siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF
TWI414301B (zh) 以微核醣核酸miＲ－１４１為標的治療小核醣核酸病毒感染
WO2007084359A2 (fr) Compositions et procedes pour le traitement des infections grippales
CA3163139A1 (fr) Compositions et methodes pour le traitement du cancer
US20210332364A1 (en) siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF
WO2024175707A1 (fr) Oligonucléotide synthétique pour le traitement d'infections à nidovirales
WO2005113014A1 (fr) ARNsi À VP-1 DE VIRUS JC ET COMPOSITION MÉDICINALE CONTENANT CELUI-CI
JP2024501762A (ja) アンジオテンシン変換酵素２（ａｃｅ２）の発現を低減させるためのオリゴヌクレオチド、及びウイルス感染を処置するためのその使用
JP2024070748A (ja) 非ゲノム配列抗ウイルス用オリゴヌクレオチド
WO2022049541A1 (fr) Molécules d'arn de silençage antiviral, molécules d'arn de silençage antiviral modifiées chimiquement présentant des capacités de pénétration cellulaire améliorées, compositions pharmaceutiques les comprenant et leurs utilisations pour le traitement d'infections virales
JP2009526516A (ja) 呼吸性ウイルス感染を処置するための組成物およびその使用
Ge et al. Pulmonary delivery of small interfering RNA for novel therapeutics
WO2008089265A2 (fr) Méthodes et compositions anti-virales
JP2005333809A (ja) ＪＣウイルスのアグノタンパク質に対するｓｉＲＮＡ、及びそれを含有してなる医薬組成物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)